📋 Browse Articles

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction
Filtered by: imaging ✕ clear all
🏷️ Tags (8587 usages)
⚗️ Metals 2487
▸ Metals — Platinum (109)
apoptosis (297)Pt (214)pt (24)ferroptosis (22)oxaliplatin (21)cisplatin (21)pyroptosis (7)necroptosis (6)transcription (6)carboplatin (5)transcription factors (5)transcriptional regulation (5)platinum (4)lead optimization (3)transcription regulation (3)metabolic adaptation (3)pt(ii) complexes (2)transcriptional regulatory interactions (2)ferroptosis induction (2)transcription initiation (2)transcription-coupled repair (2)adaptive binding (2)cellular adaptation (2)post-transcriptional regulation (2)pt(dach)methionine (1)transcription-coupled nucleotide excision repair (tc-ner) (1)triptolide (1)molecular optimization (1)pt(dach)cl4 (1)innate apoptotic immunity (1)pta (1)oligopeptides (1)transcription-coupled ner (1)ferroptosis suppressor protein 1 (fsp1) (1)apoptotic cells (1)platinumbased (1)hptab (1)signaling-transcriptional mechanisms (1)oncogene transcription inhibition (1)pt2 (1)admet optimization (1)receptor (1)pten (1)platinum(ii) (1)chain-of-thought prompt engineering (1)tetrapeptides (1)apoptotic function (1)adaptive immune response (1)gpt-2 (1)platinum drugs (1)ptii complex (1)platinum complexes (1)transcriptomics (1)cell metabolism disruption (1)peptide (1)pt(s,s-dab) (1)pt(r,r-dab) (1)pt3(hptab) (1)estrogen receptor (1)transcriptional addiction (1)transcription stress (1)septicemia (1)optical spectroscopies (1)receptors (1)selective serotonin reuptake inhibitors (ssri) (1)transcription-coupled nucleotide excision repair (1)pt(r,r-dach) (1)chiroptical response (1)diplatinum helicate (1)cyclometalated 1,3-bis(8-quinolyl) phenyl chloroplatinum(ii) (1)transcriptional activity (1)pt1 (1)disrupting a base pair (1)platinum-containing drugs (1)gpt-4 (1)transcriptional stalling (1)transcription inhibition (1)apoptotic (1)eukaryotic transcription (1)base pairing disruption (1)apoptosis-related disorders (1)coordination chemistry is not relevant, but bioinorganic and medicinal chemistry are related concepts (1)chatgpt (1)apoptosis induction (1)platinum(ii)-based (1)transcriptional activation (1)platinum-based compounds (1)inhibition of transcription factors (1)molecular descriptors (1)pt(dach)oxalato (1)polypeptide chains (1)pt(dach)cl2 (1)glp-1 receptor agonists (1)chiroptical applications (1)pt(s,s-dach) (1)cell-penetrating peptides (1)cysteine uptake (1)therapeutic optimization (1)shape description methods (1)transcription blockage (1)antiferroptotic (1)rna transcription (1)electronic absorption (1)cellular adaptation to hypoxia (1)ferroptosis suppressor protein 1 (1)apoptosis evasion (1)phosphopeptide-based kinome analysis (1)anti-apoptotic (1)gpt (1)
▸ Metals — Cobalt (185)
coordination-chemistry (102)Co (64)coordination chemistry (55)colorectal cancer (19)computational biology (7)spectroscopy (7)computational chemistry (6)computational modeling (6)pharmacology (6)co (5)pharmacovigilance (5)cryo-electron microscopy (4)glucose (4)colon cancer (4)metal complexes (4)glycolysis (4)oncology (4)pharmacokinetics (4)conformational change (3)glycocalyx (3)oncometabolite (3)complex i (3)oncosis (3)oncogenesis (2)polypharmacology (2)in-silico (2)plant secondary metabolites (2)computational approaches (2)in silico (2)convolutional neural networks (2)complex iii (2)natural compounds (2)pharmacodynamics (2)mitochondrial complex i (2)aerobic glycolysis (2)oncogene (2)covid-19 (2)microviscosity (1)pharmacometabolomics (1)complex formation (1)redox control (1)fatty alcohols (1)influence on physicochemical properties (1)fluorescence recovery after photobleaching (1)convolutional neural network (1)conditional lethality (1)picolinic acid (1)sars-cov-1 (1)metabolic control (1)pharmacological inhibition (1)pharmacokinetic (1)therapeutic controversy (1)multicolor emission (1)co2 fixation (1)protein complex (1)oncogenes (1)recombination (1)confocal microscopy (1)metal-ligand cooperation (1)cell surface recognition (1)sarcoma (1)network pharmacology (1)covalent interaction (1)escherichia coli (1)cobalamin (1)reversible compartmentalization (1)oncogene promoter regions (1)cellular compartments (1)coulometric karl fischer apparatus (1)combinatorial treatment (1)heme-containing enzymes (1)coimmunoprecipitation assay (1)glycosphingolipids (1)comorbidities (1)glycolytic activity (1)computational metabolomics (1)conformational isomerization (1)constitutive induction (1)confocal imaging (1)alcoholic hepatitis (1)knowledge discovery (1)oncogenic mutation (1)cobaltocene (1)coordination (1)computational approach (1)inorganic compounds (1)toxicology (1)conformational stability (1)connectivity mapping (1)mitochondrial uncoupling protein 2 (1)pharmacokinetic analyses (1)membrane permeability comparison (1)computer models (1)pathological conditions (1)dna condensation (1)4-octyl-itaconate (4-oi) (1)glucose dependence (1)cockayne's syndrome (1)atomic force microscope (1)complex diseases (1)dna conformational distortion (1)computational prediction (1)health economics (1)viscometry (1)conformational transitions (1)anticoagulant (1)glycome (1)oncogenic pathways (1)mitochondrial quality control (1)spin-orbit coupling (1)cytosolic ca21 concentration (1)cobamide (1)glycobiology (1)coimmunoprecipitation (1)dual protein expansion microscopy (1)brightfield microscopy (1)complexes (1)fluorescence recovery after photobleaching (frap) (1)glucose deprivation resistance (1)physicochemical properties (1)cell-like compartments (1)expansion microscopy (1)anticoagulants (1)ascorbic acid (1)oncogenic signaling (1)collective intelligence (1)cordycepin (1)genetic encoding (1)co2 (1)coupled-cluster computations (1)atp-competitive inhibitors (1)non-covalent interaction (1)computational methods (1)conformational states (1)conformational transition (1)electronic health records (1)sars-cov-2 (1)computational models (1)pharmacodynamic (1)text encoder (1)social cognition (1)sensory nerve conduction velocity (1)covalent binding (1)oncogene-mediated cellular transformation (1)fluorescence microscopy (1)glycolysis pathway (1)electronic conductometry (1)conformational landscapes (1)inductively coupled plasma mass spectrometry (1)itaconate (1)co(terpy)2+ (1)nmr spectroscopy (1)computational analysis (1)inductively coupled plasma mass spectrometer (1)coenzyme q10 (1)cell communication (1)colony formation assay (1)physico-chemical mechanisms (1)recognition (1)glycolytic enzymes (1)systems pharmacology (1)atomic force microscopy (1)computational methodologies (1)oncogenic (1)click expansion microscopy (1)glycosylation (1)n-(2-picolyl)salicylimine (1)ewing sarcoma (1)computational study (1)anticoagulation (1)confocal laser scanning microscopy (1)immuno-oncology (1)genome conformation profiling (1)somatic comorbidities (1)uv-vis spectroscopy (1)in silico analysis (1)co-immunoprecipitation (1)caco-2 cell monolayers (1)scoping review (1)conformational switch (1)damage recognition (1)entity recognition (1)energy conversion (1)noncovalent interactions (1)computer analysis (1)
▸ Metals — Iron (60)
▸ Metals — Ruthenium (86)
Ru (41)drug discovery (27)drug-delivery (23)drug resistance (11)prodrug (9)drug-drug interactions (9)drugs (7)adverse drug reactions (7)structural biology (7)drug repurposing (6)drug delivery (5)drug (5)drug development (5)g-quadruplex dna (4)ru (4)protein structure (3)drug interactions (3)structural analysis (3)drug screening (3)drug-target interaction prediction (3)g-quadruplex (3)drug design (3)drug repositioning (2)metallodrugs (2)structural data (2)drug-target interaction (2)serum (1)structure-based virtual screening (1)recruitment (1)hexammineruthenium(iii) (1)drug testing (1)spectrum diagrams (1)drug therapy (1)drug safety monitoring (1)drug sensitivity and resistance testing (1)drug safety assessment (1)structure (1)structural insights (1)adverse drug reaction detection (1)drug sensitization (1)drug target (1)truncations (1)drug-drug interaction prediction (1)protein structure-function relationship (1)pyruvate (1)drug-drug interaction identification (1)phenotypic drug screening (1)spontaneous adverse drug reaction reports (1)structural basis (1)antiviral drug discovery (1)drug tolerance (1)green rust (1)structural modeling (1)small-molecule drugs (1)structural methods (1)drug-nutrient interactions (1)adverse drug events (1)computational drug discovery (1)metal-based drugs (1)structural rearrangement (1)protein structure analysis (1)virus (1)small-molecule oral drugs (1)targeted drug delivery (1)adverse drug reaction (1)chemical drugs (1)doxorubicin (1)drug resistance reduction (1)drug-likeness (1)drug interaction prediction (1)drug target identification (1)macromolecular structure determination (1)resorufin (1)drug interaction analysis (1)drug combinations (1)non-steroidal anti-inflammatory drugs (nsaids) (1)structural bioinformatics (1)structure prediction (1)drug response (1)drug interaction screening (1)ruthenium(ii)-based (1)drug detection (1)structure-function analysis (1)metal-based drug (1)protocellular structures (1)drug interaction identification (1)
▸ Metals — Copper (63)
▸ Metals — Gold (19)
▸ Metals — Iridium (29)
▸ Metals — Others (17)
▸ Metals — Palladium (13)
▸ Metals — Zinc (5)
▸ Metals — Other (17)
🔬 Methods 1116
▸ Methods — Other experimental (213)
synthesis (244)ML (51)docking (23)natural language processing (12)in vitro (7)in vivo (6)morphological profiling (4)literature search (4)benchmarking (4)network analysis (4)image-based profiling (3)biochemical analysis (3)text analysis (3)bibliometric analysis (3)api (2)incites (2)vosviewer (2)experimental (2)theoretical studies (2)high-throughput screening (2)sequence analysis (2)information extraction (2)pubmed (2)cck-8 assay (2)statistics (2)lectin array (2)statistical approach (2)literature review (2)genetic (2)icite (2)lectin microarray (2)semantic search (2)data visualization (1)in vivo studies (1)target-based approaches (1)permeability measurement (1)gene expression profile (1)patch clamp (1)cnns (1)knockout mouse studies (1)cpg island methylator phenotype (1)in vitro models (1)immunoblot (1)bret2 (1)preclinical models (1)graph theory (1)gnns (1)passive rheology (1)nonequilibrium sensitivity analysis (1)ex vivo (1)multilayer network integration (1)inhibition assay (1)go analysis (1)experimental data analysis (1)caspase activity (1)nct (1)esm (1)web of science (1)gene expression microarray (1)uv light exposure (1)text2sql (1)decision-making (1)short tandem repeat profiling (1)in-vitro (1)analytical determination methods (1)perturbation (1)immunospecific antibodies (1)overexpression (1)mechanistic analysis (1)nuclease digestion (1)enzymatic reaction (1)excision assay (1)nuclear magnetic resonance (not explicitly mentioned but implied through study of variants) (1)pampa assay (1)experimental studies (1)null models (1)binding studies (1)clinical analysis (1)semi-supervised learning (1)efficacy analyses (1)supervised learning (1)electric field application (1)mouse model (1)estimates (1)isothermal calorimetry (1)rational design (1)learning to rank (1)gene expression analysis (1)fluorometry (1)octanol-aqueous shake-flask method (1)polypharmacy regimens (1)predictive models (1)xr-seq (1)graph learning (1)human studies (1)in vivo lung perfusion (1)merip-seq (1)uv-detection (1)atp hydrolysis (1)clinical methods (1)data processing (1)glovebox-bound apparatus (1)hoechst 33,258 staining (1)mutational analyses (1)semantic retrieval (1)solid-phase microextraction (1)immunization (1)pathscan array (1)quantitative phase behavior (1)natural bond orbital (nbo) analysis (1)ai (1)immunological analysis (1)cellular assays (1)synthetic biology tools (1)nanotherapeutic approaches (1)splicing regulation profiling (1)genome-wide screening (1)loss-of-function screens (1)histochemical staining (1)resazurin reduction assay (1)stopped-flow ph jump experiments (1)protein language model (1)experimental validation (1)matrix factorization (1)giao method (1)multi-head attention mechanism (1)rnns (1)phase ii trial (1)calorimetry (1)high throughput screening (1)trp emission (1)self-supervised learning (1)chemocentric approach (1)graph-based learning (1)tcga analysis (1)theoretical framework (1)machine-learning algorithms (1)ablation experiments (1)boolean logic (1)guanidine hydrochloride denaturation (1)ic50 index (1)statistical analysis (1)quantification (1)ensemble learning (1)in vitro study (1)relation search (1)relation extraction (1)image segmentation (1)genetic studies (1)genome-wide analysis (1)knockdown (1)ccsd(t) (1)biochemical characterization (1)performance evaluation (1)nbo 3.1 (1)rocplotter (1)mitoplast preparation (1)cryoem (1)entity annotation (1)modeling (1)systems engineering (1)database analysis (1)radiation exposure (1)prognostic tools (1)mouse models (1)nuclear magnetic resonance (1)proximity ligation assays (1)mp2(fc)/6–311 +  + (2d,2p) (1)personalized treatments (1)ncbi e-utilities (1)gradient boosting machines (1)kegg analysis (1)genetic algorithm (1)algorithms (1)experimental design (1)system-level/network analyses (1)visualized analysis (1)aimall (1)radiotherapy (1)laboratory methods (1)displacement assay (1)electrophoretic retardation measurements (1)seahorse platform (1)normoxia (1)mixture modeling (1)high-throughput (1)experimental methods (1)slot blot (1)magnetic tweezers (1)thermal denaturation (1)global genome ner (1)genetic profiling (1)mutation analysis (1)algorithm development (1)modelling (1)cell migration assay (1)methylome profiling (1)biochemical studies (1)patch clamping (1)umbrella review (1)zotero (1)immunoblotting (1)statistical methods (1)cellular models (1)miclip (1)fluorometric assay (1)enzymatic assays (1)genetic analysis (1)photophysical (1)biomedical information retrieval (1)logistic regression (1)in-vivo (1)mutational status analysis (1)
▸ Methods — Computational (31)
▸ Methods — Crystallography / Structure (4)
▸ Methods — Cell biology (21)
▸ Methods — Spectroscopy (19)
▸ Methods — Genomics / Omics (25)
▸ Methods — Mass spec / Chromatography (6)
▸ Methods — Clinical / Epidemiology (8)
▸ Methods — Electrochemistry (5)
▸ Methods — Other (1)
🎯 Targets 980
▸ Targets — Mitochondria (15)
▸ Targets — Other (157)
protein (58)enzyme (19)heme (11)gene expression (10)nucleus (9)genome (5)cardiolipin (5)enzymes (5)are (4)nucleolus (4)genetic variants (4)tfiih (4)lipids (4)signal transduction (4)cytoplasm (4)cellular metabolism (4)cell metabolism (3)cell surface (3)ribosome (3)metalloproteins (3)cells (3)cell (3)fumarate hydratase (2)dihydroorotate dehydrogenase (2)ubiquinone (2)stress response (2)tubulin (2)cytosol (2)polysulfides (2)cytochrome c oxidase (2)xpb (2)aif (2)genes (2)ribosome biogenesis (2)chromophore (1)none (1)substrates (1)clinical notes (1)acsl4 (1)protein phosphatase 2a (1)dpscs (1)albumin (1)tissues (1)trxr (1)substrate (1)platelet aggregation (1)tbk1 (1)metabolic phenotype (1)lab results (1)intracellular ph (1)sqr (1)cellular biochemistry (1)target (1)healthy cells (1)sting (1)gene targets (1)variants (1)three-way junction (1)heme-oxygenase1 (1)ddr1 (1)cajal bodies (1)target genes (1)upr (1)mif (1)heme a3 (1)nucleic acids (1)intracellular substrates (1)hydrogen sulfide (h2s) (1)mt1-mmp (1)gene (1)plasma proteins (1)adenine (1)metabolic signatures (1)nuclear foci (1)mscs (1)caspase cascade (1)p65 (1)dna synthesis (1)ddb2 (1)nuclear factor (1)hmga2 (1)ecm (1)diseases (1)spliceosomal proteins (1)neurons (1)smn protein (1)nadh/nad(p)h (1)rtk clusters (1)reactive species (1)metal (1)translation initiation (1)ligand (1)lipid droplet (1)metabolic enzymes (1)pkcd (1)protein kinases (1)peripheral nervous system (1)stem cells (1)cellular targets (1)metalloenzyme (1)chemical reactions (1)4ebp1 (1)procaspase 3 (1)ump synthase (1)rbx1 (1)literature-based evidence (1)ras (1)metabolic biomarkers (1)guanine (1)metal centers (1)ccr7 (1)cytochrome p450 2e1 (1)cell nucleus (1)lung tissue (1)ph (1)stress granules (1)erythrocytes (1)hexokinase 2 (1)nucleic acid (1)nitrogen species (1)four-way junction (1)nucleolar protein (1)p21 (1)mek1/2 (1)membrane potential (1)polysulfides (h2sn) (1)mek (1)annexin v (1)atp production (1)actin (1)traf5 (1)tme (1)cytoskeleton (1)proteoforms (1)cell cycle (1)p47phox (1)metabolome (1)cellular (1)aldoa (1)oxidants (1)zbp1 (1)cellular machines (1)atp (1)actin filaments (1)disease network (1)lipid damage (1)focal adhesions (1)p97 (1)protein sequence (1)xpc (1)whole cell (1)p38 (1)plectin (1)plasmids (1)propidium iodide (1)nadph oxidase 1 (nox1) (1)hdac enzymes (1)
▸ Targets — Nucleic acids (44)
▸ Targets — Membrane / Transport (15)
▸ Targets — Enzymes / Kinases (18)
▸ Targets — Transcription factors (5)
🦠 Diseases 880
▸ Diseases — Cancer (69)
▸ Diseases — Other (41)
▸ Diseases — Neurodegenerative (18)
▸ Diseases — Inflammatory / Immune (6)
▸ Diseases — Metabolic (5)
▸ Diseases — Cardiovascular (6)
▸ Diseases — Hepatic / Renal (8)
⚙️ Mechanisms 800
▸ Mechanisms — ROS / Redox (65)
▸ Mechanisms — Other (96)
cell cycle arrest (16)enzyme inhibition (12)phosphorylation (5)gene expression regulation (5)cell cycle regulation (4)persulfidation (3)detoxification (3)ligand dissociation (2)sequence variants (2)mechanism of action (2)resistance (2)inactivation (2)invasion inhibition (1)er stress responses (1)hormesis (1)invasiveness (1)epithelial-to-mesenchymal transition inhibition (1)oxygen-dependent metabolism (1)aquation (1)paracellular permeability (1)translation efficiency (1)denaturation (1)sequestration (1)oxidative post-translational modification (1)lipid metabolism (1)duplex unwinding (1)unfolded protein response (1)antioxidation (1)calcium regulation (1)radical formation (1)oxidative damage (1)splicing regulation (1)cell growth arrest (1)protein destabilization (1)multivalent interactions (1)protein phosphatase 2a modulation (1)protein dislocation (1)cell growth suppression (1)proteotoxic stress (1)protein rearrangements (1)p21 translation inhibition (1)gg-ner (1)pseudohypoxia (1)hypoxic response (1)electron shuttle (1)low-barrier hydrogen bond (1)kinase inhibition (1)synthetic lethality (1)stress responses (1)mutagenesis (1)subcellular relocalization (1)weak interactions (1)proton ejection (1)metabolic fuel selection (1)posttranslational modification (1)regulatory interactions (1)proton pumps (1)genetic regulation (1)protein unfolding (1)nucleolar homeostasis (1)ligand switch (1)ribosomopathies (1)oxidation-reduction (1)induced fit (1)localization (1)genetic mutation (1)mode of action (1)nucleolar stress response (1)cell killing capacity (1)ligand exchange (1)bond breaking (1)kinase activation (1)modulation (1)diadduct formation (1)cytoskeleton modulation (1)radical-mediated reaction (1)electron self-exchange (1)protein shuttling (1)pore formation (1)cellular metabolism regulation (1)nuclear export processes (1)ion selectivity (1)cell survival suppression (1)stabilization (1)cell damage (1)mitochondrial bioenergetics (1)gene therapy (1)cytochrome p450 2e1 inhibition (1)oxidative metabolic phenotype (1)phosphorylation regulation (1)aggregation (1)downregulation (1)glutamate exchange (1)acidosis (1)dysregulated gene expression (1)glycan expression (1)
▸ Mechanisms — Signaling (51)
▸ Mechanisms — Immune modulation (21)
▸ Mechanisms — DNA damage / Repair (5)
▸ Mechanisms — Epigenetic (18)
▸ Mechanisms — Cell death (7)
▸ Mechanisms — Protein interaction (14)
▸ Mechanisms — Metabolic rewiring (8)
🔗 Ligands 659
▸ Ligands — N-donor (25)
▸ Ligands — Heterocyclic (9)
▸ Ligands — C-donor / NHC (4)
▸ Ligands — S-donor (14)
▸ Ligands — O-donor (7)
▸ Ligands — Other (8)
▸ Ligands — P-donor (2)
▸ Ligands — Peptide / Protein (4)
▸ Ligands — Macrocyclic (3)
▸ Ligands — Polydentate (5)
🧠 Concepts 612
▸ Concepts — Other biomedical (178)
medicinal chemistry (122)photoactivated (27)cell biology (13)chemotherapy (11)metabolism (10)biochemistry (9)artificial intelligence (7)large language models (7)systems biology (6)information retrieval (5)precision medicine (5)gene regulation (5)data mining (5)chemoprevention (4)cheminformatics (4)therapeutic target (4)mitophagy (4)immunology (4)genetics (4)biomedical research (3)large language model (3)biomedical literature (3)hydrogen bonding (3)post-translational modifications (3)chemotherapy resistance (3)variant interpretation (3)immunometabolism (3)physiology (2)clinical practice (2)evidence extraction (2)biotransformation (2)metabolic regulation (2)physiological relevance (2)chemical biology (2)cell cycle progression (2)immunomodulation (2)biophysics (2)protein modification (2)biopharmaceutics (2)immunity (2)in vitro modeling (2)post-translational modification (2)targeted therapy (2)predictive modeling (2)therapy resistance (2)desiccant efficiency (1)multimodal data integration (1)stereochemistry (1)variant evaluation (1)epithelial-mesenchymal transition (1)metalloprotein (1)genetic screening (1)self-assembly (1)personalized therapy (1)protein function prediction (1)cellular mechanisms (1)protein targeting (1)evidence-based medicine (1)photophysics (1)protein modifications (1)translational research (1)paracellular transport (1)helicase mechanism (1)chemiosmosis (1)polarizability (1)nonequilibrium (1)genotype characterization (1)nuclear shape (1)nutrient dependency (1)metabolic engineering (1)interactome (1)therapies (1)probing (1)multiscale analysis (1)reactive species interactome (1)tissue-specific (1)pharmaceutics (1)knowledge extraction (1)metabolic activities (1)protein function (1)chemical ontology (1)proton delocalization (1)permeability (1)biomarkers (1)prediction tool (1)mechanisms of action (1)protein-ligand binding affinity prediction (1)short hydrogen bonds (1)chemical language models (1)biomedical informatics (1)organelle function (1)microbiome (1)pathogenesis (1)mechanistic framework (1)biosignatures (1)cellular stress response (1)ion-selective electrodes (1)multimodal fusion (1)gasotransmitter (1)carbon metabolism (1)bioengineering (1)ion association (1)enzyme mechanism (1)symmetry breaking (1)micropolarity (1)genome stability (1)scaffold (1)global health (1)clinical implications (1)cellular neurobiology (1)mesh indexing (1)llm (1)therapeutic strategy (1)ner (1)dissipative behavior (1)enzymology (1)pretrained model (1)longevity (1)profiling approaches (1)multimodal information integration (1)therapeutic implications (1)astrobiology (1)protein sequence analysis (1)selective degradation (1)mechanical properties (1)biomedical literature search (1)metabolism regulation (1)extracellular vesicles (1)protein chemistry (1)foundation model (1)data science (1)low-barrier hydrogen bonds (1)variant detection (1)synthetic biology (1)therapeutic innovation (1)therapeutic targeting (1)metabolic dependencies (1)protein data bank (1)cellular biology (1)phenotypic screening (1)immunoengineering (1)database (1)thermochemistry (1)therapeutic approaches (1)medical subject heading (1)network biology (1)inorganic chemistry (1)immunoregulation (1)ageing (1)protein interaction networks (1)hormone mimics (1)therapeutics (1)chemotherapy efficacy (1)metabolite-mediated regulation (1)regulatory landscape (1)chemical informatics (1)mental well-being (1)personalized medicine (1)cell plasticity (1)protein science (1)metabolic therapy (1)cell polarity (1)bioavailability (1)biomedicine (1)cellular stress (1)network medicine (1)energy transduction (1)boron helices (1)nucleolar biology (1)sialic acid (1)organic solvent drying (1)phenotypic analysis (1)in vivo perfusion (1)polypharmacy (1)hyperglycemia (1)phenotypic screens (1)mechanobiology (1)nuclear organization (1)
▸ Concepts — Bioinorganic (7)
▸ Concepts — Thermodynamics / Kinetics (10)
▸ Concepts — Evolution / Origin of life (9)
▸ Concepts — Nanomedicine / Delivery (2)
▸ Concepts — Cancer biology (1)
📦 Other 583
▸ Other (169)
review (375)proteins (11)cytochrome c (10)hydrogen sulfide (5)lactate (3)lipid (3)fumarate (3)kras (3)inhibitors (2)spermidine (2)csa (2)persulfides (2)xtb (2)catalase (2)csb (2)putrescine (2)metalloenzymes (2)mental health (1)carbonate ions (1)antithrombotic agents (1)pik3ca (1)butionine sulfoximine (1)prmt5 (1)uniprotkb (1)tpp-hclo4 (1)brequinar (1)pubtator 3.0 (1)metal salt (1)na-h2tcpp (1)nadhp (1)genotoxic agents (1)modular interaction motifs (1)npm1 protein (1)protons (1)ribosome biogenesis factors (1)nadh (1)ki-67 (1)chemistry (1)phosphatidic acid (1)heat shock proteins (1)l-ohp (1)brain (1)association study (1)ucp2 (1)alkaline phosphatase (1)trex1 (1)insp7 (1)ribosomal proteins (1)chebi (1)platelet aggregation inhibitors (1)artificial metalloenzymes (1)fluorescent probe (1)charge balancing (1)o-nitrophenyl octyl ether (1)dataset (1)resazurin (1)gfp (1)gap junctions (1)vitamin b12 (1)organic solutes (1)garlic oil (1)cationic surfactant (1)ligand charges (1)3-phenylquinazolinones (1)dodecyl-β-d-maltoside (1)r16 (1)bacterial anti-phage systems (1)uvssa (1)protein-templated synthesis (1)2-nitrophenyloctyl ether (1)atovaquone (1)tpp (1)p62 (1)ms023 (1)boron-doped helical systems (1)uv photoproducts (1)triton x-100 (1)tight binding (1)alkylating agents (1)bml284 (1)sodium azide (az) (1)phospholipids (1)mediator (1)snu13 (1)dithiothreitol (dtt) (1)cystine (1)proton pump inhibitors (1)mtt (1)adda 5 (1)rpa (1)ac220 (1)sodium decanoate (1)nad (1)lipophilic ionic additive (1)hdac inhibitor (1)methylene blue (1)greigite (1)sucralose (1)dspe-peg-2000 (1)bpep (1)phospholipid (1)diallyltrisulfide (1)pyrene (1)replication protein a (1)polynucleotide synthesis (1)eloxatine (1)drt (1)plasticity (1)nop56 (1)silicate (1)phosphoinositides (1)intrinsically disordered proteins (1)metoprolol (1)box c/d rnp (1)nop1 (1)dmf (1)diuretics (1)atp analogue (1)ribonuclease inhibitors (1)ligand properties (1)monoclonal antibodies (1)adp•bef3 (1)organic carbon (1)folfox-6 (1)desiccants (1)nadph (1)physical activity (1)minoxidil (1)hydrogel (1)st101 (1)pyrazino[2,3-d]pyridazine (1)tight-binding (1)rhea (1)cytochrome oxidase (1)astrocytes (1)decanol (1)elof1 (1)extended tight-binding (1)nucleophosmin (1)nsc49l (1)entinostat (1)insp6 (1)gsk-3β (1)mannosides (1)prmt1 inhibitor (1)lcs-1 (1)sleep quality (1)arginine (1)pp-insps (1)oligonucleotides (1)organic solvents (1)networks (1)bora[7]helicene (1)bardoxolone (1)insp8 (1)pluronic f-127 (1)probes (1)npm1 (1)pvc (1)heart aging (1)therapeutic agents (1)thapsigargin (1)brivudine (1)charge-balancing workflow (1)diborahelicate (1)folfox (1)pyp (1)tfiie (1)dpep (1)
🧬 Activities 402
▸ Activities — Catalytic / Sensing (15)
▸ Activities — Other biological (110)
inhibition (6)regulation (5)chemoresistance (5)therapeutic (4)oxidation (4)cell survival (4)cell growth (3)prediction (3)chemopreventive (2)target identification (2)phagocytosis (2)analysis (2)carcinogenesis (2)degradation (2)adr detection (2)treatment (2)cell viability (2)vesicle formation (2)cellular response (2)weight loss (2)therapy (2)survival (2)immunomodulatory (2)binding (2)neurotoxicity (2)photodynamic therapy (2)emission (1)incidence (1)protein degradation (1)protein expression (1)ribonuclease activity (1)therapeutic advances (1)protein interaction analysis (1)detection (1)protection (1)sulfide oxidase (1)model training (1)medication (1)diagnostic (1)toxicity (1)enzyme activity (1)transformation (1)physiological function (1)nitrification (1)data extraction (1)postmarketing surveillance (1)explanation (1)neuroprotection (1)functional regulators (1)prognosis (1)immunosuppression (1)signal production (1)personalized treatment (1)electron shuttling (1)morphological analysis (1)metabolic plasticity (1)myocardial ischemic injury (1)cell division (1)replication (1)nucleolar reorganization (1)multi-target (1)probe biology (1)promoting angiogenesis (1)oled (1)cell lysis (1)screening (1)carbon fixation (1)epigenome profiling (1)hypoxia alleviation (1)wound healing (1)question answering (1)ammonia oxidation (1)modulation of cytoskeleton (1)ppi prediction (1)cellular protection (1)gene function prediction (1)metabolic (1)cell invasion (1)cell line characterization (1)ddi screening (1)immunosuppressive (1)cellular transformation (1)profiling (1)tubulin inhibition (1)interactions (1)cell growth promotion (1)sensitization (1)mutation prevention (1)predictive biomarker (1)nucleolar stress (1)energy homeostasis (1)stimulation (1)carbon limitation response (1)stress regulation (1)cell migration (1)anti-ageing (1)regulatory assessment (1)prognostic value (1)evaluation (1)variant prioritization (1)induction (1)intracellular ph regulation (1)cell profiling (1)regulation of calcium levels (1)rare disease diagnosis (1)disease gene identification (1)therapeutic opportunities (1)invasion (1)metabolic activity (1)protein synthesis (1)
▸ Activities — Antimicrobial (3)
▸ Activities — Anticancer (3)
▸ Activities — Antioxidant / cytoprotect (2)

🔍 Filters

96 articles with selected tags
Niki Tavakoli, Emma J Fong, Abigail Coleman +9 more · 2024 · bioRxiv : the preprint server for biology · Cold Spring Harbor Laboratory · added 2026-04-20
Cancer-associated fibroblasts (CAFs) play a key role in metabolic reprogramming and are well-established contributors to drug resistance in colorectal cancer (CRC). To exploit this metabolic crosstalk Show more
Cancer-associated fibroblasts (CAFs) play a key role in metabolic reprogramming and are well-established contributors to drug resistance in colorectal cancer (CRC). To exploit this metabolic crosstalk, we integrated a systems biology approach that identified key metabolic targets in a data-driven method and validated them experimentally. This process involved a novel machine learning-based method to computationally screen, in a high-throughput manner, the effects of enzyme perturbations predicted by a computational model of CRC metabolism. This approach reveals the network-wide effects of metabolic perturbations. Our results highlighted hexokinase (HK) as a crucial target, which subsequently became our focus for experimental validation using patient-derived tumor organoids (PDTOs). Through metabolic imaging and viability assays, we found that PDTOs cultured in CAF-conditioned media exhibited increased sensitivity to HK inhibition, confirming the model predictions. Our approach emphasizes the critical role of integrating computational and experimental techniques in exploring and exploiting CRC-CAF crosstalk. Show less
no PDF DOI: 10.1101/2024.05.24.595756
ML imaging
Mikheeva, Alesya M., Bogomolov, Mikhail A., Gasca, Valentina A. +4 more · 2024 · Nature Publishing Group · Nature · added 2026-04-20
Imaging-based anticancer drug screens are becoming more prevalent due to development of automated fluorescent microscopes and imaging stations, as well as rapid advancements in image processing softwa Show more
Imaging-based anticancer drug screens are becoming more prevalent due to development of automated fluorescent microscopes and imaging stations, as well as rapid advancements in image processing software. Automated cell imaging provides many benefits such as their ability to provide high-content data, modularity, dynamics recording and the fact that imaging is the most direct way to access cell viability and cell proliferation. However, currently most publicly available large-scale anticancer drugs screens, such as GDSC, CTRP and NCI-60, provide cell viability data measured by assays based on colorimetric or luminometric measurements of NADH or ATP levels. Although such datasets provide valuable data, it is unclear how well drug toxicity measurements can be integrated with imaging data. Here we explored the relations between drug toxicity data obtained by XTT assay, two quantitative nuclei imaging methods and trypan blue dye exclusion assay using a set of four cancer cell lines with different morphologies and 30 drugs with different mechanisms of action. We show that imaging-based approaches provide high accuracy and the differences between results obtained by different methods highly depend on drug mechanism of action. Selecting AUC metrics over IC50 or comparing data where significantly drugs reduced cell numbers noticeably improves consistency between methods. Using automated cell segmentation protocols we analyzed mitochondria activity in more than 11 thousand drug-treated cells and showed that XTT assay produces unreliable data for CDK4/6, Aurora A, VEGFR and PARP inhibitors due induced cell size growth and increase in individual mitochondria activity. We also explored several benefits of image-based analysis such as ability to monitor cell number dynamics, dissect changes in total and individual mitochondria activity from cell proliferation, and ability to identify chromatin remodeling drugs. Finally, we provide a web tool that allows comparing results obtained by different methods. Show less
📄 PDF DOI: 10.1038/s41420-024-01950-3
anticancer imaging mitochondria
2024 · Cancer & Metabolism · BioMed Central · added 2026-04-20
Background Hypoxia is a common feature of many solid tumors and causes radiotherapy and immunotherapy resistance. Pharmacological inhibition of oxidative phosphorylation (OXPHOS) has emerged as a ther Show more
Background Hypoxia is a common feature of many solid tumors and causes radiotherapy and immunotherapy resistance. Pharmacological inhibition of oxidative phosphorylation (OXPHOS) has emerged as a therapeutic strategy to reduce hypoxia. However, the OXPHOS inhibitors tested in clinical trials caused only moderate responses in hypoxia alleviation or trials were terminated due to dose-limiting toxicities. To improve the therapeutic benefit, FDA approved OXPHOS inhibitors (e.g. atovaquone) were conjugated to triphenylphosphonium ­( TPP+) to preferentially target Show less
📄 PDF DOI: 10.1186/s40170-024-00342-6
imaging
PN Beerkens, J Bussink, TW Secomb +159 more · 2024 · Cancer & Metabolism · BioMed Central · added 2026-04-20
PN Beerkens, J Bussink, TW Secomb, R Hsu, ET Ong, JF Gross, MW Dewhirst, JM Brown, DF Boreel, PN Span, S Heskamp, GJ Adema, SE Rademakers, JH Kaanders, FC Sweep, AJ van der Kogel, MC Joiner, DR Grimes, M Partridge, JT Coates, M Skwarski, GS Higgins, US Gaipl, G Multhoff, H Scheithauer, K Lauber, S Hehlgans, B Frey, TM Ashton, E Fokas, LA Kunz-Schughart, LK Folkes, S Anbalagan, M Huether, KTY Han, A Fyles, T Shek, J Croke, N Dhani, D D’Souza, DR McGowan, E Belcher, F Di Chiara, D Stavroulias, M McCole, TA Yap, N Daver, M Mahendra, J Zhang, C Kamiya-Matsuoka, F Meric-Bernstam, F Janku, P LoRusso, AS Mansfield, R Nanda, A Spira, T Wang, G Cheng, M Hardy, P Topchyan, R Zander, P Volberding, W Cui, J Zielonka, O Ouari, M Lopez, D McAllister, K Boyle, J Joseph, A Sikora, J Vasquez-Vivar, IC Summerhayes, TJ Lampidis, SD Bernal, JJ Nadakavukaren, KK Nadakavukaren, EL Shepherd, JS Modica-Napolitano, JR Aprille, FM Veronese, G Pasut, M Busk, J Overgaard, MR Horsman, J Lok, SP Burr, AS Costa, GL Grice, RT Timms, IT Lobb, P Freisinger, LD Falo, M Kovacsovics-Bankowski, K Thompson, KL Rock, K Rohlenova, K Sachaphibulkij, J Stursa, A Bezawork-Geleta, J Blecha, B Endaya, Z Bielcikova, L Krizova, L Dong, J Spacek, S Hlousek, A Nagelkerke, FCGJ Sweep, JM Newton, A Hanoteau, HC Liu, A Gaspero, F Parikh, RD Gartrell-Corrado, JM Henk, PB Kunkler, CW Smith, GO Janssens, CH Terhaard, PA Doornaert, HP Bijl, P van den Ende, JR Molina, Y Sun, M Protopopova, S Gera, M Bandi, C Bristow, T Lofton, M Smith, CA Bristow, A Carugo, M Benej, X Hong, S Vibhute, S Scott, J Wu, E Graves, S Nadanaciva, A Bernal, R Aggeler, R Capaldi, Y Will, QY Li, Y Huang, M Fiorillo, R Lamb, HB Tanowitz, L Mutti, M Krstic-Demonacos, AR Cappello, M Huang, D Xiong, J Pan, Q Zhang, Y Wang, CR Myers, RP Garay, R El-Gewely, JK Armstrong, G Garratty, P Richette Show less
Background Hypoxia is a common feature of many solid tumors and causes radiotherapy and immunotherapy resistance. Pharmacological inhibition of oxidative phosphorylation (OXPHOS) has emerged as a the Show more
Background Hypoxia is a common feature of many solid tumors and causes radiotherapy and immunotherapy resistance. Pharmacological inhibition of oxidative phosphorylation (OXPHOS) has emerged as a therapeutic strategy to reduce hypoxia. However, the OXPHOS inhibitors tested in clinical trials caused only moderate responses in hypoxia alleviation or trials were terminated due to dose-limiting toxicities. To improve the therapeutic benefit, FDA approved OXPHOS inhibitors (e.g. atovaquone) were conjugated to triphenylphosphonium (TPP + ) to preferentially target cancer cell’s mitochondria. In this study, we evaluated the hypoxia reducing effects of several mitochondria-targeted OXPHOS inhibitors and compared them to non-mitochondria-targeted OXPHOS inhibitors using newly developed spheroid models for diffusion-limited hypoxia. Methods B16OVA murine melanoma cells and MC38 murine colon cancer cells expressing a HIF-Responsive Element (HRE)-induced Green Fluorescent Protein (GFP) with an oxygen-dependent degradation domain (HRE-eGFP-ODD) were generated to assess diffusion-limited hypoxia dynamics in spheroids. Spheroids were treated with IACS-010759, atovaquone, metformin, tamoxifen or with mitochondria-targeted atovaquone (Mito-ATO), PEGylated mitochondria-targeted atovaquone (Mito-PEG-ATO) or mitochondria-targeted tamoxifen (MitoTam). Hypoxia dynamics were followed and quantified over time using the IncuCyte Zoom Live Cell-Imaging system. Results Hypoxic cores developed in B16OVA.HRE and MC38.HRE spheroids within 24 h hours after seeding. Treatment with IACS-010759, metformin, atovaquone, Mito-PEG-ATO and MitoTam showed a dose-dependent reduction of hypoxia in both B16OVA.HRE and MC38.HRE spheroids. Mito-ATO only alleviated hypoxia in MC38.HRE spheroids while tamoxifen was not able to reduce hypoxia in any of the spheroid models. The mitochondria-targeted OXPHOS inhibitors demonstrated stronger anti-hypoxic effects compared to the non-mito-targeted OXPHOS inhibitors. Conclusions We successfully developed a high-throughput spheroid model in which hypoxia dynamics can be quantified over time. Using this model, we showed that the mitochondria-targeted OXPHOS inhibitors Mito-ATO, Mito-PEG-ATO and MitoTam reduce hypoxia in tumor cells in a dose-dependent manner, potentially sensitizing hypoxic tumor cells for radiotherapy. Supplementary Information The online version contains supplementary material available at 10.1186/s40170-024-00342-6. Show less
📄 PDF DOI: 10.1186/s40170-024-00342-6
amino-acid imaging mitochondria
Christie A. Bader, Peter V. Simpson, Elena Dallerba +9 more · 2024 · Dalton Transactions · Royal Society of Chemistry · added 2026-04-20
Morpholine motifs have been used extensively as targeting moieties for lysosomes, primarily in fluorescence imaging agents. Traditionally these imaging agents are based on organic molecules wh Show more
Morpholine motifs have been used extensively as targeting moieties for lysosomes, primarily in fluorescence imaging agents. Traditionally these imaging agents are based on organic molecules which have several shortcomings including small Stokes shifts, short emission lifetimes, and susceptibility to photobleaching. To explore alternative lysosome targeting imaging agents we have used a rhenium based phosphorescent platform which has been previously demonstrated to have an improved Stokes shift, a long lifetime emission, and is highly photostable. Rhenium complexes containing morpholine substituted ligands were designed to accumulate in acidic compartments. Two of the three complexes prepared exhibited bright emission in cells, when incubated at low concentrations (20 μM) and were non-toxic at concentrations as high as 100 μM, making them suitable for live cell imaging. We show that the rhenium complexes are amenable to chemical modification and that the morpholine targeted derivatives can be used for live cell confocal fluorescence imaging of endosomes–lysosomes. Show less
📄 PDF DOI: 10.1039/D3DT03067A
Re imaging synthesis
Aviva Levina, Kartika Wardhani, Liam J. Stephens +7 more · 2024 · Dalton Transactions · Royal Society of Chemistry · added 2026-04-20
Rhenium(I) tricarbonyl complexes are widely studied for their cell imaging properties and anti-cancer and anti-microbial activities, but the complexes with S-donor ligands remain relatively un Show more
Rhenium(I) tricarbonyl complexes are widely studied for their cell imaging properties and anti-cancer and anti-microbial activities, but the complexes with S-donor ligands remain relatively unexplored. A series of six fac-[Re(NN)(CO)3(SR)] complexes, where (NN) is 2,2′-bipyridyl (bipy) or 1,10-phenanthroline (phen), and RSH is a series of thiocarboxylic acid methyl esters, have been synthesized and characterized. Cellular uptake and anti-proliferative activities of these complexes in human breast cancer cell lines (MDA-MB-231 and MCF-7) were generally lower than those of the previously described fac-[Re(NN)(CO)3(OH2)]+ complexes; however, one of the complexes, fac-[Re(CO)3(phen)(SC(Ph)CH2C(O)OMe)] (3b), was active (IC50 ∼ 10 μM at 72 h treatment) in thiol-depleted MDA-MB-231 cells. Moreover, unlike fac-[Re(CO)3(phen)(OH2)]+, this complex did not lose activity in the presence of extracellular glutathione. Taken together these properties show promise for further development of 3b and its analogues as potential anti-cancer drugs for co-treatment with thiol-depleting agents. Conversely, the stable and non-toxic complex, fac-[Re(bipy)(CO)3(SC(Me)C(O)OMe)] (1a), predominantly localized in the lysosomes of MDA-MB-231 cells, as shown by live cell confocal microscopy (λex = 405 nm, λem = 470–570 nm). It is strongly localized in a subset of lysosomes (25 μM Re, 4 h treatment), as shown by co-localization with a Lysotracker dye. Longer treatment times with 1a (25 μM Re for 48 h) resulted in partial migration of the probe into the mitochondria, as shown by co-localization with a Mitotracker dye. These properties make complex 1a an attractive target for further development as an organelle probe for multimodal imaging, including phosphorescence, carbonyl tag for vibrational spectroscopy, and Re tag for X-ray fluorescence microscopy. Show less
📄 PDF DOI: 10.1039/D4DT00149D
Co MCF-7 Re X-ray imaging mitochondria pyridine synthesis
Monika Kopeć, Aleksandra Borek-Dorosz, Karolina Jarczewska +2 more · 2024 · Analyst · Royal Society of Chemistry · added 2026-04-20
In this paper, we present Raman imaging as a non-invasive approach for studying changes in mitochondrial metabolism caused by cardiolipin–cytochrome c interactions. We investigated the effect Show more
In this paper, we present Raman imaging as a non-invasive approach for studying changes in mitochondrial metabolism caused by cardiolipin–cytochrome c interactions. We investigated the effect of mitochondrial dysregulation on cardiolipin (CL) and cytochrome c (Cyt c) interactions for a brain cancer cell line (U-87 MG). Mitochondrial metabolism was monitored by checking the intensities of the Raman bands at 750 cm−1, 1126 cm−1, 1310 cm−1, 1337 cm−1, 1444 cm−1 and 1584 cm−1. The presented results indicate that under pathological conditions, the content and redox status of Cyt c in mitochondria can be used as a Raman marker to characterize changes in cellular metabolism. This work provides evidence that cardiolipin–cytochrome c interactions are crucial for mitochondrial energy homeostasis by controlling the redox status of Cyt c in the electron transport chain, switching from disabling Cyt c reduction and enabling peroxidase activity. This paper provides experimental support for the hypothesis of how cardiolipin–cytochrome c interactions regulate electron transfer in the respiratory chain, apoptosis and mROS production in mitochondria. Show less
📄 PDF DOI: 10.1039/D4AN00015C
imaging mitochondria
Bradley J. Schwehr, David Hartnell, Gaewyn Ellison +8 more · 2024 · Analyst · Royal Society of Chemistry · added 2026-04-20
Neurobiological research relies heavily on imaging techniques, such as fluorescence microscopy, to understand neurological function and disease processes. However, the number and variety of fl Show more
Neurobiological research relies heavily on imaging techniques, such as fluorescence microscopy, to understand neurological function and disease processes. However, the number and variety of fluorescent probes available for ex vivo tissue section imaging limits the advance of research in the field. In this review, we outline the current range of fluorescent probes that are available to researchers for ex vivo brain section imaging, including their physical and chemical characteristics, staining targets, and examples of discoveries for which they have been used. This review is organised into sections based on the biological target of the probe, including subcellular organelles, chemical species (e.g., labile metal ions), and pathological phenomenon (e.g., degenerating cells, aggregated proteins). We hope to inspire further development in this field, given the considerable benefits to be gained by the greater availability of suitably sensitive probes that have specificity for important brain tissue targets. Show less
no PDF DOI: 10.1039/D4AN00663A
imaging review
Gianna M Colombo, Steven M Corsello · 2024 · Cancer research · added 2026-04-20
Over the past three decades, high-throughput phenotypic cancer cell line screens have revealed unanticipated small-molecule activities and illuminated connections between tumor genotypes and anticance Show more
Over the past three decades, high-throughput phenotypic cancer cell line screens have revealed unanticipated small-molecule activities and illuminated connections between tumor genotypes and anticancer efficacy. Founded in 1984, the National Cancer Institute's "NCI60" screen laid the conceptual groundwork for the contemporary landscape of phenotypic drug discovery. NCI60 first operated as a primary bioactivity screen, but molecular characterization of the NCI60 cell line panel and development of a small-molecule sensitivity pattern recognition algorithm (called "COMPARE") have enabled subsequent studies into drug mechanisms of action and biomarker identification. In this issue of Cancer Research, Kunkel and colleagues report an updated version of the NCI60 screen, dubbed "HTS384" NCI60, that better aligns with current cell proliferation assay standards and has higher throughput. Changes include the use of a 384-well plate format, automated laboratory equipment, 3 days of compound exposure, and a CellTiter-Glo luminescent endpoint. To confirm that data from the HTS384 and classic NCI60 screen are comparable, the authors tested a library of 1,003 anticancer agents using both protocols and applied COMPARE to analyze patterns of cell line sensitivities. More than three dozen groups of targeted therapies showed high comparability between screens. Modernization of NCI60, and closer integration with other large-scale pharmacogenomic screens and molecular feature sets, will help this public screening service remain pertinent for cancer drug discovery efforts for years to come. See related article by Kunkel et al., p. 2403. Show less
no PDF DOI: 10.1158/0008-5472.CAN-24-1506
anticancer imaging
Vanha N Pham, Christopher J Chang · 2023 · Angewandte Chemie · Wiley · added 2026-04-20
Transition metal chemistry is essential to life, where metal binding to DNA, RNA, and proteins underpins all facets of the central dogma of biology. In this context, metals in proteins are typically s Show more
Transition metal chemistry is essential to life, where metal binding to DNA, RNA, and proteins underpins all facets of the central dogma of biology. In this context, metals in proteins are typically studied as static active site cofactors. However, the emergence of transition metal signaling, where mobile metal pools can transiently bind to biological targets beyond active sites, is expanding this conventional view of bioinorganic chemistry. This Minireview focuses on the concept of metalloallostery, using copper as a canonical example of how metals can regulate protein function by binding to remote allosteric sites (e.g., exosites). We summarize advances in and prospects for the field, including imaging dynamic transition metal signaling pools, allosteric inhibition or activation of protein targets by metal binding, and metal-dependent signaling pathways that underlie nutrient vulnerabilities in diseases spanning obesity, fatty liver disease, cancer, and neurodegeneration. Show less
📄 PDF DOI: 10.1002/anie.202213644
Cu amino-acid imaging
Chenggang Jiang, Louise M. Cañada, Ngoc Bao Nguyen +3 more · 2023 · Journal of the American Chemical Society · ACS Publications · added 2026-04-20
Ligand-centered functionalization reactions offer diverse strategies to prepare luminescent organometallic compounds. These compounds can have unique structures that are not accessible via traditional Show more
Ligand-centered functionalization reactions offer diverse strategies to prepare luminescent organometallic compounds. These compounds can have unique structures that are not accessible via traditional coordination chemistry and can possess enhanced or unusual photophysical properties. Here we show that bis-cyclometalated iridium bis-isocyanide complexes (1) react with azide (N3-) to form novel luminescent structures. The fate of the reaction with azide is determined primarily by the substituent on the aryl isocyanide. Those with electron-withdrawing substituents (CF3 or NO2) react with 1 equiv of azide followed by N2 extrusion, forming aryl cyanamido products (2). With electron-donating groups on the aryl isocyanide the reactivity is more diverse, and three outcomes are possible. In two cases, the isocyanide and azide undergo a [3 + 2] cycloaddition to form a C-bound tetrazolato structure (3). In three other cases, 2 equiv of azide are involved in the formation of a previously unobserved structure, where a tetrazolato and aryl cyanamido couple and rearrange to form a chelating ligand comprised of an N-bound tetrazolato and an acyclic diaminocarbene (4). Finally, a bimetallic aryl cyanamido complex (5) is isolated in one case. All compounds are luminescent, some with exceptional photoluminescence quantum yields as high as 0.81 in solution for sky-blue emission, and 0.87 for yellow emission and 0.65 for orange-red emission in polymer films. Show less
no PDF DOI: 10.1021/jacs.2c11062
Ir imaging
Konstantin G. Lyamzaev, Lyamzaev, Konstantin G. , Alisa A. Panteleeva +7 more · 2023 · Springer Berlin Heidelberg · Springer · added 2026-04-20
Ferroptosis is a regulated form of necrotic cell death reliant on iron-catalyzed lipid peroxidation. Although the precise involvement of mitochondria in ferroptosis remains incompletely elucidated, re Show more
Ferroptosis is a regulated form of necrotic cell death reliant on iron-catalyzed lipid peroxidation. Although the precise involvement of mitochondria in ferroptosis remains incompletely elucidated, recent research indicates that mitochondrial oxidative events wield a pivotal influence in this mechanism. This article centers on the most recent discoveries, spotlighting the significance of mitochondrial lipid peroxidation in the occurrence of ferroptosis. Modern investigative tools, such as mitochondria-specific dyes responsive to lipid peroxidation and antioxidants targeting mitochondria, have been employed to delve into this phenomenon. The authors’ recent empirical evidence demonstrates that mitochondrial lipid peroxidation, quantified using the innovative fluorescent ratiometric probe MitoCLox, takes place prior to the onset of ferroptotic cell death. The mitochondria-targeted antioxidant SkQ1 hinders mitochondrial lipid peroxidation and thwarts ferroptosis, all while leaving unaffected the buildup of reactive oxygen species within the cytoplasm, an antecedent to mitochondrial lipid peroxidation. Similarly, the redox agent methylene blue, impeding the genesis of reactive oxygen species in complex I of the electron transport chain, also imparts a comparable protective effect. These findings collectively imply that reactive oxygen species originating from complex I might hold particular significance in fomenting mitochondrial lipid peroxidation, a pivotal trigger of ferroptosis. Show less
no PDF DOI: 10.1007/s12551-023-01126-w
Fe ROS imaging mitochondria
Diana A Llerena Schiffmacher, Katarzyna W Kliza, Arjan F Theil +6 more · 2023 · DNA repair · Elsevier · added 2026-04-20
Transcription-blocking lesions are specifically targeted by transcription-coupled nucleotide excision repair (TC-NER), which prevents DNA damage-induced cellular toxicity and maintains proper transcri Show more
Transcription-blocking lesions are specifically targeted by transcription-coupled nucleotide excision repair (TC-NER), which prevents DNA damage-induced cellular toxicity and maintains proper transcriptional processes. TC-NER is initiated by the stalling of RNA polymerase II (RNAPII), which triggers the assembly of TC-NER-specific proteins, namely CSB, CSA and UVSSA, which collectively control and drive TC-NER progression. Previous research has revealed molecular functions for these proteins, however, exact mechanisms governing the initiation and regulation of TC-NER, particularly at low UV doses have remained elusive, partly due to technical constraints. In this study, we employ knock-in cell lines designed to target the endogenous CSB gene locus with mClover, a GFP variant. Through live cell imaging, we uncover the intricate molecular dynamics of CSB in response to physiologically relevant UV doses. We showed that the DNA damage-induced association of CSB with chromatin is tightly regulated by the CSA-containing ubiquitin-ligase CRL complex (CRL4CSA). Combining the CSB-mClover knock-in cell line with SILAC-based GFP-mediated complex isolation and mass-spectrometry-based proteomics, revealed novel putative CSB interactors as well as discernible variations in complex composition during distinct stages of TC-NER progression. Our work not only provides molecular insight into TC-NER, but also illustrates the versatility of endogenously tagging fluorescent and affinity tags. Show less
no PDF DOI: 10.1016/j.dnarep.2023.103566
DNA-binding imaging
Meenaxi Saini, Tia E. Keyes · 2023 · Dalton Transactions · Royal Society of Chemistry · added 2026-04-20
Cyclometalated 1,3-bis(8-quinolyl) phenyl chloroplatinum(II) (Pt1) shows selective luminescence transduction of G-quadruplex binding over duplex DNA. The effect is enhanced on association with Show more
Cyclometalated 1,3-bis(8-quinolyl) phenyl chloroplatinum(II) (Pt1) shows selective luminescence transduction of G-quadruplex binding over duplex DNA. The effect is enhanced on association with parallel and hybrid G-quadruplex structures over other topologies. The kinetics of binding are studied for c-myc and the response is found to be partially reversible in a displacement assay. Show less
📄 PDF DOI: 10.1039/D3DT01188G
Pt cyclometalating imaging
Shing-Lun Chan, Yuen-Kiu Chun, Chi-Chiu Ko · 2023 · Materials Chemistry Frontiers · Royal Society of Chemistry · added 2026-04-20
Transition-metal acyclic carbene complexes have received increasing attention in recent years. As acyclic carbene ligands show strong σ-donating properties comparable to N-heterocyclic carbene Show more
Transition-metal acyclic carbene complexes have received increasing attention in recent years. As acyclic carbene ligands show strong σ-donating properties comparable to N-heterocyclic carbene (NHC) ligands, transition-metal complexes with acyclic carbene ligands also demonstrate outstanding performance and functional properties similar to their NHC counterparts. Therefore, transition-metal acyclic carbene complexes are considered viable alternatives to NHC complexes in the development of metal-based functional materials. As transition-metal acyclic carbene complexes can be prepared from metal isocyanide synthetic precursors, substituents of different electronic and steric natures as well as functional moieties can be readily introduced into acyclic carbene ligands by changing the isocyanide ligand. Moreover, the open structure of acyclic carbene ligands has made their structure and the electronic properties strongly dependent on the substituents as well as the micro-environment. As a result, the functional properties of acyclic complexes can be drastically varied by rational molecular design of the ligands. The environmental sensitivity of the properties of these complexes also made them ideal for the development of stimuli-responsive materials and chemical sensors. In this article, the preparation, electronic properties and design of metal acyclic carbene complexes with different functional properties for the development of advanced materials are described. Show less
📄 PDF DOI: 10.1039/D3QM00285C
NHC catalysis coordination-chemistry imaging synthesis
Q. Dan, X. Dan, R. Jiang +1557 more · 2023 · Advanced Science · Wiley · added 2026-04-20
Q. Dan, X. Dan, R. Jiang, Z. Wang, D. Dai, L. Sun, A. Caschera, L. Lazzara, D. Piergallini, B. Ricci, A. Tuscano, F. Vanzulli, D. R. Czeyda‐Pommersheim, J. R. Martin, B. Costello, J. Kalb, N. Wallyn, S. Anton, T. F. Akram, S. N. Vandamme, M. A. Gandhi, J. G. Brown, D. A. Wong, C. B. Aguirre, N. Sirlin, E. Naseri, F. Ajorlou, Y. Asghari, N. Pilehvar‐Soltanahmadi, P. Tsapis, I. Dey, N. Blakey, V. T. C. Stone, X. Tsang, T. T. W. Li, G. S. Wong, K. D. Filonov, L.‐M. Piatkevich, J. Ting, K. Zhang, V. V. Kim, L. Verkhusha, A. R. Truong, P. Ferre‐D'Amare, P. J. Charalampaki, A. Proskynitopoulos, M. Heimann, A. J. Nakamura, M. G. Sinnamon, Y. Neuwirth, S. M. Song, S. Schultz, X. Liu, C. M. Xu, G. C. Sehgal, T. Karakousis, M. von Knorring, A. Mogensen, S. V. Upadhyay, D. Dalvi, A. Maresca, M. Lakshmanan, A. Abedi, A. Bar‐Zion, G. J. Farhadi, J. O. Lu, D. Szablowski, S. Wu, M. G. Yoo, N. Shapiro, S. von Knebel Doeberitz, L. Maksimovic, D. Loi, A. Paech, G. J. Lakshmanan, A. Lu, S. P. Farhadi, M. Nety, A. Kunth, D. Lee‐Gosselin, R. W. Maresca, M. Bourdeau, J. Yin, C. Yan, D. Witte, F. S. Malounda, L. Foster, M. G. Schroder, M. G. Shapiro, R. M. Shapiro, L. J. Ramirez, G. Sperling, J. Sun, A. Sun, D. V. Pines, V. S. Schaffer, H. Bajaj, M. W. Kang, S. Kang, H. S. Kashiwagi, V. H. Choi, A. E. Roberts, A. J. Frias, C. C. Fordham, N. Hacherl, K. Patel, B. Jones, M. Myers, J. Abraham, M. Gendreau, A. B. Ormo, K. Cubitt, L. A. Kallio, R. Y. Gross, S. J. Tsien, J. Remington, F. Wiedenmann, G. U. Oswald, N. C. Nienhaus, G. H. Shaner, M. W. Patterson, R. N. Davidson, M. W. Day, N. C. Davidson, R. E. Shaner, P. A. Campbell, B. N. G. Steinbach, A. E. Giepmans, R. Y. Palmer, M. M. Tsien, O. V. Karasev, K. A. Stepanenko, K. K. Rumyantsev, V. V. Turoverov, K. Verkhusha, C. Vintersten, M. Monetti, P. Z. Gertsenstein, L. Zhang, S. Laszlo, A. Biechele, A. Nagy, S. Amsterdam, N. Lin, T. Hopkins, A. Matsumoto, K. Suetsugu, M. Hasegawa, Y. Nakamura, H. Shibata, T. Aoki, H. Kunisada, M. Tsurumi, M. Shimizu, R. M. Bouvet, Q. T. Hoffman, E. S. Nguyen, T. A. Olson, T. Aguilera, M. Jiang, L. G. Scadeng, R. Y. Ellies, M. Tsien, B. Zhao, H. Li, F. Zhang, N. C. Zhang, J. C. Rockwell, S. H. Lagarias, S. J. Bhoo, J. Davis, B. Walker, R. D. Karniol, S. J. Vierstra, A. V. Davis, R. D. Vener, L. Vierstra, P. A. O'Brien, K. Hosick, D. E. John, T. D. Stec, X. Hinds, A. Shu, M. Z. Royant, T. A. Lin, V. Aguilera, P. A. Lev‐Ram, R. Y. Steinbach, K. D. Tsien, F. V. Piatkevich, V. V. Subach, D. M. Verkhusha, V. V. Shcherbakova, M. Shcherbakova, A. V. Baloban, M. Emelyanov, P. Brenowitz, V. V. Guo, R. Verkhusha, Y. Liu, K. Xu, Z. Xu, S. K. Dai, R. Donnelly, S. P. H. Cabrera, J. R. Mao, B. Christin, W. Wu, J. J. Guo, J. S. Bravo‐Cordero, J. E. Condeelis, L. Segall, D. M. Hodgson, O. V. Shcherbakova, K. K. Stepanenko, V. V. Baloban, J. S. Verkhusha, K. Y. Paige, S. R. Wu, E. V. Jaffrey, P. J. Dolgosheina, R. L. Unrau, M. D. Strack, S. R. Disney, K. D. Jaffrey, M. C. Warner, W. Chen, R. L. Song, A. Strack, S. R. Thorn, A. R. Jaffrey, A. Ferre‐D'Amare, E. Autour, M. Westhof, G. S. Ryckelynck, J. D. Filonov, N. Moon, S. R. Svensen, A. Jaffrey, S. C. Y. Autour, A. D. Jeng, A. Cawte, A. Abdolahzadeh, S. S. S. Galli, D. Panchapakesan, M. Rueda, P. J. Ryckelynck, A. Unrau, M. Arora, A. Sunbul, W. Jaeschke, G. S. Song, H. Filonov, M. Kim, X. Hirsch, J. D. Li, S. R. Moon, M. Jaffrey, J. I. Jaeschke, M. N. Traylor, A. C. Pernik, S. K. Sternisha, K. G. McBrayer, Y. Abdullah, Y. Harada, T. Murayama, E. Takamatsu, H. Otsuji, S. Tanaka, F. Broekx, S. Weyns, W. De Vleeschouwer, S. Stummer, S. Stocker, H. Wagner, C. Stepp, C. Fritsch, A. E. Goetz, R. Goetz, H. J. Kiefmann, W. Reulen, U. Stummer, T. Pichlmeier, O. D. Meinel, F. Wiestler, H. J. Zanella, A. L.‐G. S. Reulen, A. P. K. K. K. Group, R. Mudiyanselage, M. A. Wu, K. Leon‐Duque, M. Ren, J. You, J. Vachtenheim, E. Borovansky, I. Dimitrow, A. Riemann, M. J. Ehlers, J. Koehler, P. Norgauer, K. Elsner, M. Koenig, S. Kaatz, F. Seidenari, C. Arginelli, P. M. W. Dunsby, K. French, C. Koenig, C. Magnoni, G. Talbot, J. Ponti, P. Staley, A. K. Grogan, H. Samadi, M. S. Cui, X. Cohen, E. I. Yang, E. V. Galanzha, P. M. Shashkov, J. Y. Spring, V. P. Suen, E. I. Zharov, V. P. Galanzha, Z. Zharov, W. Habli, R. AlChamaa, H. Saab, M. L. Kadara, Y. Khraiche, F. Sun, Z. Ding, R. Chen, C. Zhang, Y. Li, Y. Xu, R. Zhang, X. Ni, G. Li, Y. Yang, P. J. Sun, B. Stang, X. Fan, X. Yang, S. Li, H. Lv, J. Zhang, L. Li, B. Wang, X. Qu, R. Peng, D. Zhang, D. Sheng, Y. Wang, K. Yao, Z. Yang, L. Wang, Y. Deng, S. Chen, M. Sirsi, L. Borden, S. V. Abou‐Elkacem, J. K. Bachawal, F. Willmann, F. Pfeifer, S. Pfeifer, P. DasSarma, A. Arora, A. Lakshmanan, A. Nety, R. W. Lee‐Gosselin, D. Bourdeau, M. G. Maresca, A. Shapiro, A. E. Oren, D. Walsby, J. M. Lee‐Gosselin, Y.‐L. Melis, R. W. Ni, D. M. Bourdeau, M. G. Kochmann, J. O. Shapiro, A. Szablowski, M. G. Bar‐Zion, P. W. Shapiro, A. Goodwill, M. Neogy, F. S. Yin, D. V. Foster, S. M. Schaffer, L. Conolly, J. Xie, T. Song, F. Jiang, R. C. Yan, M. T. Hurt, M. Buss, K. Duan, M. Y. Wong, D. P. You, M. B. Sawyer, P. Swift, P. Dutka, D. R. Barturen‐Larrea, Z. Mittelstein, M. H. Jin, R. Farhadi, M. G. Deshpande, G. H. Farhadi, D. P. Ho, R. W. Sawyer, M. G. Bourdeau, D. Shapiro, T. Maresca, A. Payen, B. Lee‐Gosselin, D. Ling, C. Malounda, M. Demene, M. G. Tanter, Z. Lakshmanan, S. P. Jin, D. P. Nety, A. Sawyer, M. B. Malounda, D. Swift, T. Hao, F. Ai, X. Goerner, V. M. Hu, M. Runge, K. M. Tweedle, A. H. Ward, R. S. Aletras, L. Balaban, T. J. Schroeder, C. Lowery, D. E. Hilty, A. Wemmer, J. J. Pines, J. Neil, A. M. Badaut, A. Fukuda, K. G. Jullienne, Y. Petry, V. S. Jasanoff, E. Lelyveld, F. H. Brustad, A. Arnold, S. M. Jasanoff, J. M. Cohen, J. G. Rifkind, E. Mohanty, P. C. M. Nagababu, S. M. van Zijl, J. A. Eleff, J. M. E. Ulatowski, A. M. Oja, R. J. Ulug, R. A. Traystman, K. Kauppinen, P. Uludag, J. P. B. Blinder, S. P. O'Connor, J. C. Robinson, H. Waterton, G. Kroll, T. Zaharchuk, J. J. Christen, M. Heit, B. Iv, G. Jacobi, S. Bongartz, A.‐C. Partovi, M. Schulte, A. B. Aschwanden, M. G. Lumsden, M. Davies, G. P. Loebe, S. Noon, J. K. Karimi, D. Lyo, R. W. Staub, D. Huegli, M. G. Bilecen, G. G. Shapiro, P. A. Westmeyer, J. O. Romero, B. Szablowski, A. Kuester, C. R. Shah, R. Otey, F. H. Langer, A. Jasanoff, L. X. Hai, T. Cai, V. S. Lee, A. Lelyveld, T. Jasanoff, L. X. Lee, V. S. Cai, A. Hai, H. Jasanoff, B. Gunshin, U. V. Mackenzie, Y. Berger, M. F. Gunshin, W. F. Romero, S. Boron, J. L. Nussberger, M. A. Gollan, B. B. Hediger, K. U. Bartelle, G. A. Szulc, J. J. Suero‐Abreu, D. H. Rodriguez, C. M. Turnbull, S. A. Lewis, R. Graves, H. F. Hernandez, T. E. Valdovinos, W. Barnhart, M. E. Cai, R. J. Meyerand, M. Nickles, P. M. Suzuki, P. Harrison, A. Arosio, J. R. Yevenes, J. Harris, Y. Marles‐Wright, R. N. Gossuin, P. Muller, L. Gillis, A. E. Bartel, Y. Z. Deans, L. M. Wadghiri, X. Bernas, B. K. Yu, D. H. Rutt, X. Turnbull, J. He, B. Cai, Y. Zhong, A. V. Qin, H. Naumova, V. Reinecke, J. Yarnykh, C. Deem, C. E. Yuan, M. Murry, V. Campan, G. D. Lionetti, F. Aquaro, M. Forini, L. Matteucci, F. Vannucci, C. Chiuppesi, M. Di Cristofano, M. Faggioni, L. Maioli, E. Barile, M. Messina, A. Lombardi, M. Pucci, F. A. Pistello, B. Recchia, E. T. Iordanova, C. Ahrens, J. Song, C. Wang, S. Mo, X. Mu, X. Jiang, Z. Zhong, G. Zhao, Y. Zhou, F. Zhuo, L. Chen, T. Kong, J. Lu, T. Yang, X. Yu, K. Shi, H. S. Li, J. Kim, J. H. Woo, H. J. Lee, Y. Joo, H. Choi, W. K. Kim, S. J. Moon, K. Kim, C. M. Bernau, A. M. Lewis, M. S. Petelinsek, D. J. Reagan, V. B. Niles, E. Mattis, M. Meyerand, C. N. Suzuki, M. Svendsen, H. Wang, F. He, Y. Gao, S. C. Guo, L. J. Beeman, J. F. Mandarino, K. M. Georges, P. C. Bennett, J. M. Ulatowski, F. Kauppinen, C. Mickoleit, S. Jorke, D. S. Geimer, J. P. Maier, J. Muller, C. Demut, D. Grafe, J. H. Schuler, J. Clement, E. C. H. Liu, R. C. Cheng, S.‐H. Long, L. Yang, P.‐H. Wang, J. Cheng, D. Yang, H. Wu, A. W. S. Mao, S. M. Chan, D. Pereira, S. R. Moss, P. Williams, A. Murray, B. Taylor, X. Todorich, B. Zhang, W. E. Slagle‐Webb, J. R. Seaman, T. T. Connor, D. H. Li, C. D. C. Chung, S. V. Allen, F. M. Torti, J. G. Torti, C. Y. Cyster, F. M. Chen, E. C. Brodsky, M. C. Niemi, W. E. Nakamura, M. R. Seaman, P. S. Daws, T. B. Patrick, M. I. Rodrigues, S. K. Kettunen, A. A. Lyons, K. M. Neves, R. Brindle, R. Blakemore, D. Uebe, S. Schueler, M. Meriaux, B. Boucher, Y. Marty, S. Lalatonne, L. Preveral, C. T. Motte, F. Lefevre, F. Geffroy, M. Lethimonnier, D. Pean, G. Garcia, D. Adryanczyk‐Perrier, N. Pignol, T. Ginet, S. Orlando, E. Mannucci, G. Fantechi, S. Conti, A. Tambalo, C. Busato, L. Innocenti, R. Ghin, P. Bassi, F. Arosio, C. Orsini, M. Sangregorio, M. F. Corti, P. Casula, A. Marzola, A. Lascialfari, P. Sbarbati, M. D. Tartaj, S. Morales, T. Veintemillas‐Verdaguer, C. J. Gonzalez‐Carreno, K. Serna, C. Grunberg, B. M. Wawer, D. Tebo, Z. Schuler, X. Xiang, J. Yang, W. Xu, Z. Lai, J. Hu, L. Tian, Q. Geng, E. Fang, M. Erdal, Y. Demirbilek, O. Yeh, L. Akbal, D. Ruff, A. Bozkurt, Y. Cabuk, B. Senel, O. Gumuskaya, S. Algin, S. Colak, E. B. Esener, M. Denkbas, F. Boucher, S. Geffroy, E. Bellanger, G. Selingue, M. Adryanczyk‐Perrier, C. T. Pean, D. Lefevre, S. Ginet, D. E. Meriaux, R. Goldhawk, A. Rohani, N. Sengupta, F. S. Gelman, K. M. Prato, A. C. Jones, M. D. Pollard, B. Pagel, G. Wu, M. Warnock, C. Zaiss, M. Lin, Z. Chen, L. Zhou, D. Mu, R. Nanz, G. Tuura, Y. Delso, Y. Jia, K. Chen, Y. Geng, Y. Cheng, J. Li, H. Qiu, R. Huang, R. P. R. Krishnamoorthy, P. Nanga, H. Bagga, R. Hariharan, S. Reddy, M. Chen, Y. Jiang, B. Yuan, Z.‐X. Zhang, C. Jiang, X. Ye, C. Yuan, S. Wang, J. Kuddannaya, D. R. Zhang, Z. Arifin, P. Han, G. Walczak, J. W. M. Liu, P. C. M. Bulte, N. N. van Zijl, G. Yadav, K. W. Y. Song, M. T. Chan, M. T. McMahon, A. A. McMahon, J. Y. Gilad, P. Z. Zhou, J. W. M. Sun, J. Y. van Zijl, J. F. Zhou, D. A. Payen, R. J. Wilson, P. C. M. Traystman, N. van Zijl, A. X. McVicar, D. F. Li, M. Goncalves, S. O. Bellyou, M. A. M. Meakin, R. Prado, A. Bartha, Y. Sakata, T. Fushimi, Y. Okada, T. Arakawa, S. Kunieda, A. Minamiguchi, N. Kido, S. Sakashita, K. Miyamoto, B. Togashi, K. Joo, Y. S. Han, S.‐K. Choi, S. S. Lee, J. H. Ahn, S.‐G. Chang, S. H. Kang, C. Zhou, C. Su, L. Liu, J. Zhao, J. Jiang, S. Zhang, W. Li, J. Zhu, Y. S. Wang, S. S. Choi, S.‐K. Ahn, J. H. Lee, S. Zhou, C. G. Jiang, Y. Eberhart, H.‐Y. Zhang, Z. Heo, L. Wen, H. Blair, M. Qin, A. Lim, J. D. Quinones‐Hinojosa, P. B. Weingart, M. G. Barker, J. Pomper, P. C. M. Laterra, J. O. van Zijl, J. Blakeley, H. Zhou, H. Yu, T. Lou, X. Zou, Z. Jiang, Y. Huang, C. Du, L. Jiang, J. Ma, W. Zhu, Q. He, J. Rui, Z. Zhou, S. Wen, H. Jiang, Y. Lu, Y. Feng, D.‐H. Heo, J. Lee, C. Wen, X. Su, M. Zhou, S.‐Y. Wang, M. Li, J.‐Y. Chen, D.‐T. Zhou, C. Peng, Y.‐M. Zhang, M. Dai, X. Wang, C.‐F. Hong, Q. Chang, B. Li, H. Ma, H.‐Y. Xiang, Y. Heo, D.‐H. Zhang, S. Lee, R. C. Leigh, P. C. M. Koehler, J. van Zijl, J. Wang, H.‐K. Zhou, K. Jeong, J. Han, Y. S. Zhao, X. Ahn, Y. Ma, Y. Bai, X. Lin, T. Hong, E. M. Ma, J. Haacke, J. Zhou, M. Wang, P. C. M. Zhou, G. W. J. van Zijl, Y. K. Harston, N. Tee, T. W. Blockley, S. Okell, G. Thandeswaran, F. Shaya, M. Sheerin, S. Cellerini, P. Payne, M. Jezzard, J. Chappell, A. Kennedy, J. Tietze, I. K. Blicher, L. Mikkelsen, M. K. Ostergaard, S. A. Strother, M. J. Smith, R. J. Donahue, T. F. Harris, L. M. Cloughesy, P. L. Liau, A. Nghiemphu, W. B. Lai, B. M. Pope, R. J. Ellingson, R. M. Liau, J. P. Prins, D. Antonios, W. H. Li, W. B. Yong, A. Pope, P. L. Lai, B. M. Nghiemphu, K. Ellingson, A. Cai, D. R. Singh, R. P. R. Roalf, M. Nanga, H. Haris, R. Gur, K. Reddy, M. Cai, A. Haris, F. Singh, J. H. Kogan, H. Greenberg, J. A. Hariharan, R. Detre, F. Reddy, A. Kogan, C. Singh, M. Debrosse, K. Haris, R. P. Cai, H. Elliott, K. A. Reddy, R. P. R. Davis, S. Nanga, S. H. Das, P. N. Chen, J. R. Hadar, T. H. Pollard, R. T. Lucas, B. Shinohara, H. Litt, M. A. Hariharan, J. A. Elliott, D. R. Reddy, P. E. Nanga, H. Rupert, M. Hariharan, M. E. Quarmley, E. Calkins, K. Dress, M. A. Prabhakaran, P. J. Elliott, R. C. Moberg, R. E. Gur, B. I. Reddy, K. P. Turetsky, A. N. O'Grady, B. D. Dula, L. M. Lyttle, B. N. Thompson, B. A. Conrad, L. J. Box, S. McKeithan, F. Pawate, B. A. Bagnato, P. Landman, S. A. Newhouse, M. Smith, K. Nath, R. Singh, F. Crescenzi, G. Kogan, S. Verma, H. Reddy, E. R. Hariharan, R. Melhem, P. Reddy, S. Bagga, R. Pickup, D. Crescenzi, A. Martinez, K. Borthakur, A. D'Aquilla, G. Singh, J. A. Verma, J. Detre, J. Reddy, L. Pepin, M.‐A. Francelle, L. Carrillo‐de Sauvage, P. de Longprez, K. Gipchtein, J. Cambon, E. Valette, J. Brouillet, W. Flament, R. R. Ling, G. Regatte, A. Navon, S. Jerschow, A. J. R. Glyn‐Jones, R. Palmer, A. J. Agricola, T. L. Price, H. Vincent, A. J. Weinans, Y. H. Carr, H.‐K. Yang, J.‐S. Jeong, S. Suh, R. Brinkhof, V. Nizak, J. J. Khlebnikov, D. W. J. Prompers, D. B. F. Klomp, X. Saris, N. N. Xu, L. Yadav, J. Knutsson, R. Hua, E. Kalyani, J. Hall, J. Laterra, R. Blakeley, M. Strowd, P. Pomper, K. W. Y. Barker, G. Chan, M. T. Liu, R. D. McMahon, P. C. M. Stevens, K.‐P. Weygand, A. S. R. Hwang, Y. Mohamed, C. D. Ding, S. Y. Fuller, S. J. Lai, J. Frank, K. W. Y. Zhou, Y. McMahon, G. Kato, Z. M. Bulte, D. Bhujwalla, P. C. M. Artemov, S. van Zijl, R. Walker‐Samuel, F. Ramasawmy, M. Torrealdea, V. Rega, S. P. Rajkumar, S. Johnson, M. Richardson, H. G. Goncalves, E. Parkes, D. L. Arstad, R. B. Thomas, M. F. Pedley, X. Lythgoe, P. C. M. Golay, C. K. van Zijl, J. Jones, C. R. Ren, A. D. Malloy, C. O. Sherry, J. Miller, E. Y. Cao, B. M. Chekmenev, A. D. Damon, J. C. Cherrington, G. L. Gore, A. J. W. Simegn, F. C. Van der Kouwe, E. M. Robertson, A. Meintjes, M. Alhamud, R. Wyss, K. Kaddurah‐Daouk, R.‐W. Cai, X. J. Tain, F. C. Zhou, A. M. Damen, H. Scotti, H. Hariharan, R. Poptani, H. Singh, W. Poptani, H. Lu, X. J. Hariharan, R. Zhou, Z. Reddy, Y. Nguyen, J. L. Chen, Z. Shaw, E. Dawkins, D. Marbyn, C. Li, R. P. R. DeBrosse, N. Nanga, K. Wilson, M. D'Aquilla, F. Hariharan, K. Yan, N. Wade, D. Sara, C. Worsley, E. Parris‐Skeete, R. McCormick, Z. Z. Xiao, L. Cunningham, K. L. Fishbein, D. R. Nathanson, V. A. Lynch, M. Stallings, M. J. Yudkoff, R. Falk, S. E. Reddy, X.‐Y. McCormack, F. Xie, E. C. Wang, J. Lin, D. F. Xu, J. C. Gochberg, Z. Gore, S. Zu, A. A. Meier, J. A. Gilad, C. Brandon, E. Qian, J. F. Gao, M. Abisambra, M. J. Vandsburger, P. C. M. Donahue, S. Donahue, C. R. Rane, M. K. Thompson, A. O. Strother, S. A. Scott, Z. Smith, F. Hu, X. Huang, X. Guo, S. Quan, X. Zhou, Z. Zhao, F. Wen, S. Huang, X. Lu, D. Hu, J. Zu, K. Zhou, Z. Yan, C. Fu, K. Yang, D.‐H. Jiang, H.‐Y. Lee, R. N. Zhang, J. E. Cole, J. Van Eyk, J. Zaiss, S. Windschuh, D. Goerke, J.‐E. Paech, S. Meissner, P. Burth, W. Kickingereder, M. Wick, H.‐P. Bendszus, M. E. Schlemmer, P. Ladd, A. Bachert, C. K. Radbruch, M. J. Jones, P. C. M. Schlosser, M. G. van Zijl, X. Pomper, J. Golay, J. O. Zhou, M. Hua, M. G. Laterra, P. C. M. Pomper, M. Zhu, L. Lim, A. Blair, S. A. Quinones‐Hinojosa, C. G. Messina, M. G. Eberhart, P. B. Laterra, P. C. M. Barker, A. N. Blakeley, S. Dula, L. M. Pawate, B. N. Dethrage, B. E. Conrad, R. L. Dewey, S. A. Barry, A. N. Smith, E. M. Dula, B. A. Asche, E. B. Landman, S. Welch, S. Pawate, J. C. Sriram, S. A. Gore, J. A. Smith, J. M. Wells, H. E. O'Callaghan, N. M. Holmes, R. A. Powell, B. Johnson, F. Siow, O. Torrealdea, S. Ismail, X. Walker‐Samuel, M. Golay, S. Rega, M. J. Modat, S. Cardoso, A. J. Ourselin, Z. Schwarz, T. K. Ahmed, M. J. Murray, E. C. O'Neill, N. Collins, M. F. Colgan, J. Lythgoe, C. van Zijl, A. Schleich, L. Mueller‐Lutz, J. Zimmermann, B. Boos, H.‐J. Schmitt, G. Wittsack, F. Antoch, M. Miese, Q. Kim, M.‐P. Chan, K. M. C. Anthony, D. Cheung, P.‐L. Samartzis, C. Khong, M. Mueller‐Lutz, B. Eichner, F. Schmitt, B. Matuschke, C. Bittersohl, H.‐J. Zilkens, C. Miese, F. Mueller‐Lutz, P. Matuschke, R. Sewerin, B. Sengewein, B. Schmitt, H.‐J. Ostendorf, K. Wittsack, G. Stanke, R. P. R. Haris, A. Nanga, K. Singh, F. Cai, H. Kogan, M. Kogan, C. Cai, H. Nanga, J. J. Reddy, T. Chung, J. H. Jin, S.‐G. Lee, E. Kim, M. Rerich, A. Zaiss, M. E. Korzowski, F. Bachert, R. B. Kogan, E. K. Stafford, G. E. Englund, H. Gold, R. Reddy, D. Bammer, P. W. Le Bihan, P. E. Schaefer, R. G. Grant, L. Gonzalez, M. Zhang, Z. Tang, J. Min, X. Lei, N. M. Henderson, K. de Souza, S. F. Thomas, V. A. Riches, S. A. Morgan, D. P. Sohaib, C. C. Dearnaley, N. J. Parker, V. van As, R. Granata, O. Fusco, B. Catalano, F. Guarino, F. Granata, A. Tatangelo, M. Avallone, R. Piccirillo, F. Palaia, A. Izzo, P. Petrillo, L. S. Agre, M. King, W. B. Yasui, O. P. Guggino, Y. Ottersen, A. Fujiyoshi, S. Engel, I. Nielsen, A. Direito, M. A. Madeira, G. Brito, G. Soveral, G.‐Y. Tang, H. Tomita, A. J. Dorward, E. Yool, A. R. Smith, T. J. Townsend, J. E. Price, A. S. Hardingham, A. J. Verkman, P.‐w. Smith, L. Phuan, M. O. Tradtrantip, J. A. Anderson, J. I. Hubbard, D. K. Szu, E. A. Binder, O. P. Nagelhus, M. C. Ottersen, A. S. Papadopoulos, C. Verkman, E. Iacovetta, R. Rudloff, M. Kirby, G. Xiao, B. Hu, Y. Desai, B. Hsu, J. G. Schneller, A. I. Hobbs, A. Mehta, S. Linninger, M. C. Saadoun, A. M. Papadopoulos, J. Fukuda, H. Badaut, C. Chu, H. Huang, J. Ding, Z. Dong, X. Gao, Q. Tang, C. Dong, J. Mai, T. Li, T. Wang, Y.‐L. Lu, J. Lan, T. Zhao, S. Ma, Y.‐L. Li, X. Lan, J.‐C. Wang, X.‐C. Lou, B. Ma, V. Zhang, F. Gradinaru, J. Ramakrishnan, R. Mattis, I. Prakash, I. Diester, K. R. Goshen, K. Thompson, Y.‐W. Deisseroth, P. Shieh, P. Minguez, J. J. Bork, D. L. Auburger, G. Guilbride, B. Kramer, E. Bukau, J. N. Natan, S. A. Wells, J. A. Teichmann, A. Marsh, H. C. Mukherjee, P. Davis, G. J. Ramesh, M. G. Lu, Y. Shapiro, B. W. Wang, E. J. Roose, V. Palovcak, I. J. Carnevale, J. P. F. Dmochowski, K. Werner, Y. Mishra, P. Huang, S. Vetschera, A. Glasl, K. Chmyrov, V. Richter, A. C. Ntziachristos, P. Stiel, K. Vetschera, J. P. Mishra, A. Fuenzalida‐Werner, V. Chmyrov, K. Stiel, K. Ono, K. Fuma, M. Tabata, H. S. Sawada, H. R. Kim, S. H. Cho, J. S. Choi, W. K. Woo, Y. Moon, H. S. Choi, K.‐W. Kim, K.‐M. Cho, Y. J. Lee, S.‐J. Yi, H. J. Eun, S. H. Woo, T.‐K. Choi, C. Whangbo, D.‐Y. Choi, W. K. Noh, S. Moon, R. Cheng, Y. Mi, G. Xu, J. Jin, Y. Zhang, F. Chen, C. Liu, D. Jiang, E. M. Wu, B. Haacke, H. Cohen, G. Dafni, A. Meir, M. Harmelin, M.‐R. Neeman, A. Lisy, C. Hartung, D. Lang, W. Schueler, J. R. Richter, W. A. Reichenbach, I. Kaiser, A. Hilger, Y. Bar‐Shir, K. W. Y. Liang, A. A. Chan, J. W. M. Gilad, D. I. Bulte, A. Piraner, H. C. Farhadi, D. Davis, D. Wu, J. O. Maresca, M. G. Szablowski, G. Farhadi, M. Ho, B. Kunth, A. Ling, R. W. Lu, L. Bourdeau, M. G. Schroeder, G. J. Shapiro, A. Farhadi, M. G. Mukherjee, J. O. Farhadi, S. R. Lee‐Gosselin, A. Barnes, R. W. Lakshmanan, M. Shapiro, E. Bekiesinska‐Figatowska, K. Sawicka, O. Zak, J. Szczygielski, L. Stritzker, M. Kirscher, N. C. Scadeng, S. Deliolanis, P. Morscher, K. Symvoulidis, Q. Schaefer, M. Buckel, U. Hess, W. G. Donat, V. Bradley, A. A. Ntziachristos, T. Szalay, A. Repenko, A. Rix, J. Nedilko, A. Rose, R. Hermann, S. Vinokur, R. Moli, M. Cao‐Milan, G. Mayer, A. von Plessen, L. Fery, W. De Laporte, D. N. Lederle, A. J. C. Chigrin, J. E. Kuehne, Z. Lemaster, A. Wang, F. Hariri, Y. Hu, C. V. Huang, R. Barback, N. C. Cochran, J. V. Gianneschi, R. J. Jokerst, A. E. Paproski, K. Forbrich, M. M. Wachowicz, R. J. Hitt, A. Zemp, F. Farhadi, G. G. Sigmund, M. G. Westmeyer Show less
Abstract Imaging contrast agents are widely investigated in preclinical and clinical studies, among which biogenic imaging contrast agents (BICAs) are developing rapidly and playing an increasingly i Show more
Abstract Imaging contrast agents are widely investigated in preclinical and clinical studies, among which biogenic imaging contrast agents (BICAs) are developing rapidly and playing an increasingly important role in biomedical research ranging from subcellular level to individual level. The unique properties of BICAs, including expression by cells as reporters and specific genetic modification, facilitate various in vitro and in vivo studies, such as quantification of gene expression, observation of protein interactions, visualization of cellular proliferation, monitoring of metabolism, and detection of dysfunctions. Furthermore, in human body, BICAs are remarkably helpful for disease diagnosis when the dysregulation of these agents occurs and can be detected through imaging techniques. There are various BICAs matched with a set of imaging techniques, including fluorescent proteins for fluorescence imaging, gas vesicles for ultrasound imaging, and ferritin for magnetic resonance imaging. In addition, bimodal and multimodal imaging can be realized through combining the functions of different BICAs, which helps overcome the limitations of monomodal imaging. In this review, the focus is on the properties, mechanisms, applications, and future directions of BICAs. Show less
📄 PDF DOI: 10.1002/advs.202207090
Fe amino-acid imaging review
Liam J. Stephens, Elena Dallerba, Jenisi T. A. Kelderman +5 more · 2023 · Dalton Transactions · Royal Society of Chemistry · added 2026-04-20
Twelve Re(I) tricarbonyl diimine (2,2′-bipyridine and 1,10-phenanthroline) complexes with thiotetrazolato ligands have been synthesised and fully characterised. Structural characterisation rev Show more
Twelve Re(I) tricarbonyl diimine (2,2′-bipyridine and 1,10-phenanthroline) complexes with thiotetrazolato ligands have been synthesised and fully characterised. Structural characterisation revealed the capacity of the tetrazolato ligand to bind to the Re(I) centre through either the S atom or the N atom with crystallography revealing most complexes being bound to the N atom. However, an example where the Re(I) centre is linked via the S atom has been identified. In solution, the complexes exist as an equilibrating mixture of linkage isomers, as suggested by comparison of their NMR spectra at room temperature and 373 K, as well as 2D exchange spectroscopy. The complexes are photoluminescent in fluid solution at room temperature, with emission either at 625 or 640 nm from the metal-to-ligand charge transfer excited states of triplet multiplicity, which seems to be exclusively dependent on the nature of the diimine ligand. The oxygen-sensitive excited state lifetime decay ranges between 12.5 and 27.5 ns for the complexes bound to 2,2′-bipyrdine, or between 130.6 and 155.2 ns for those bound to 1.10-phenanthroline. Quantum yields were measured within 0.4 and 1.5%. The complexes were incubated with human lung (A549), brain (T98g), and breast (MDA-MB-231) cancer cells, as well as with normal human skin fibroblasts (HFF-1), revealing low to moderate cytotoxicity, which for some compounds exceeded that of a standard anti-cancer drug, cisplatin. Low cytotoxicity combined with significant cellular uptake and photoluminescence properties provides potential for their use as cellular imaging agents. Furthermore, the complexes were assessed in disc diffusion and broth microdilution assays against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), Escherichia coli (E. coli), and Pseudomonas aeruginosa (P. aeruginosa) bacterial strains, which revealed negligible antibacterial activity in the dark or after irradiation. Show less
📄 PDF DOI: 10.1039/D2DT03237F
A549 NMR Re antibacterial anticancer imaging pyridine synthesis
Slyskova J, Muniesa-Vargas A, da Silva IT +11 more · 2023 · NAR cancer · Oxford University Press · added 2026-04-20
The therapeutic efficacy of cisplatin and oxaliplatin depends on the balance between the DNA damage induction and the DNA damage response of tumor cells. Based on clinical evidence, oxaliplatin is adm Show more
The therapeutic efficacy of cisplatin and oxaliplatin depends on the balance between the DNA damage induction and the DNA damage response of tumor cells. Based on clinical evidence, oxaliplatin is administered to cisplatin-unresponsive cancers, but the underlying molecular causes for this tumor specificity are not clear. Hence, stratification of patients based on DNA repair profiling is not sufficiently utilized for treatment selection. Using a combination of genetic, transcriptomics and imaging approaches, we identified factors that promote global genome nucleotide excision repair (GG-NER) of DNA-platinum adducts induced by oxaliplatin, but not by cisplatin. We show that oxaliplatin-DNA lesions are a poor substrate for GG-NER initiating factor XPC and that DDB2 and HMGA2 are required for efficient binding of XPC to oxaliplatin lesions and subsequent GG-NER initiation. Loss of DDB2 and HMGA2 therefore leads to hypersensitivity to oxaliplatin but not to cisplatin. As a result, low DDB2 levels in different colon cancer cells are associated with GG-NER deficiency and oxaliplatin hypersensitivity. Finally, we show that colon cancer patients with low DDB2 levels have a better prognosis after oxaliplatin treatment than patients with high DDB2 expression. We therefore propose that DDB2 is a promising predictive marker of oxaliplatin treatment efficiency in colon cancer. Show less
📄 PDF DOI: 10.1093/narcan/zcad057
DNA-binding Pt imaging
2023 · NAR cancer · Oxford University Press · added 2026-04-21
The therapeutic efficacy of cisplatin and oxaliplatin depends on the balance between the DNA damage induction and the DNA damage response of tumor cells. Based on clinical evidence, oxaliplatin is adm Show more
The therapeutic efficacy of cisplatin and oxaliplatin depends on the balance between the DNA damage induction and the DNA damage response of tumor cells. Based on clinical evidence, oxaliplatin is administered to cisplatin-unresponsive cancers, but the underlying molecular causes for this tumor specificity are not clear. Hence, stratification of patients based on DNA repair profiling is not sufficiently utilized for treatment selection. Using a combination of genetic, transcriptomics and imaging approaches, we identified factors that promote global genome nucleotide excision Show less
📄 PDF DOI: 10.1093/narcan/zcad057
anticancer bioinorganic cancer catalysis cisplatin ddb2 dna dna binding
Cimini, Beth A., Chandrasekaran, Srinivas Niranj, Kost-Alimova, Maria +32 more · 2023 · Nature Publishing Group · Nature · added 2026-04-20
We provide an updated protocol for image-based profiling with Cell Painting. A detailed procedure, with standardized conditions for the assay, is presented, along with a comprehensive description of p Show more
We provide an updated protocol for image-based profiling with Cell Painting. A detailed procedure, with standardized conditions for the assay, is presented, along with a comprehensive description of parameters to be considered when optimizing the assay. Show less
📄 PDF DOI: 10.1038/s41596-023-00840-9
bioimaging cell painting assay flow cytometry image-based profiling imaging
Anna Chandrasekar Murali, Prakash Nayak, Krishnan Venkatasubbaiah · 2022 · Dalton Transactions · Royal Society of Chemistry · added 2026-04-20
Tetra-coordinated boron compounds offer a plethora of luminescent materials. Different chelation around the boron center (O,O-, N,C-, N,O-, and N,N-) has been explored to tune the electronic a Show more
Tetra-coordinated boron compounds offer a plethora of luminescent materials. Different chelation around the boron center (O,O-, N,C-, N,O-, and N,N-) has been explored to tune the electronic and photophysical properties of tetra-coordinated boron compounds. A number of fascinating molecules with interesting properties such as aggregation induced emission, mechanochromism and tunable emission by changing the solvent polarity were realised. Owing to their rich and unique properties, some of the molecules have shown applications in making optoelectronic devices, probes and so on. This perspective provides an overview of the recent developments of tetra-coordinated boron compounds and their potential applications. Show less
📄 PDF DOI: 10.1039/D2DT00160H
imaging review synthesis
B Kalyanaraman · 2022 · The FASEB Journal · added 2026-04-20
Abstract Black and Hispanic cancer patients have a higher incidence of cancer mortality. Many factors (e.g., socioeconomic differences, insufficient access to healthcare) contribute to racial dispari Show more
Abstract Black and Hispanic cancer patients have a higher incidence of cancer mortality. Many factors (e.g., socioeconomic differences, insufficient access to healthcare) contribute to racial disparity. Emerging research implicates biological disparity in cancer outcomes. Studies show distinct differences in the tumor immune microenvironment (TIME) in Black cancer patients. Studies also have linked altered mitochondrial metabolism to changes in immune cell activation in TIME. Recent publications revealed a novel immunomodulatory role for triphenylphosphonium‐based mitochondrial‐targeted drugs (MTDs). These are synthetically modified, naturally occurring molecules (e.g., honokiol, magnolol, metformin) or FDA‐approved small molecule drugs (e.g., atovaquone, hydroxyurea). Modifications involve conjugating the parent molecule via an alkyl linker chain to a triphenylphosphonium moiety. These modified molecules (e.g., Mito‐honokiol, Mito‐magnolol, Mito‐metformin, Mito‐atovaquone, Mito‐hydroxyurea) accumulate in tumor cell mitochondria more effectively than in normal cells and inhibit mitochondrial respiration, induce reactive oxygen species, activate AMPK and redox transcription factors, and inhibit cancer cell proliferation. Besides these intrinsic effects of MTDs in redox signaling and proliferation in tumors, MTDs induced extrinsic effects in the TIME of mouse xenografts. MTD treatment inhibited tumor‐suppressive immune cells, myeloid‐derived suppressor cells, and regulatory T cells, and activated T cells and antitumor immune effects. One key biological disparity in Black cancer patients was related to altered mitochondrial oxidative metabolism; MTDs targeting vulnerabilities in tumor cells and the TIME may help us understand this biological disparity. Clinical trials should include an appropriate number of Black and Hispanic cancer patients and should validate the intratumoral, antihypoxic effects of MTDs with imaging. Show less
📄 PDF DOI: 10.1096/fj.202101862R
ROS anticancer imaging mitochondria
María Benítez, María L. Buil, Miguel A. Esteruelas +3 more · 2022 · Inorganic Chemistry · ACS Publications · added 2026-04-20
The preparation of three families of phosphorescent iridium(III) emitters, including iridaoxazole derivatives, hydroxycarbene compounds, and N,C(sp3),C(sp2),O-tetradentate Show more
The preparation of three families of phosphorescent iridium(III) emitters, including iridaoxazole derivatives, hydroxycarbene compounds, and N,C(sp3),C(sp2),O-tetradentate containing complexes, has been performed starting from dimers cis-[Ir(μ22-C≡CR){κ2-C,N-(MeC6H3-py)}2]2 (R = tBu (1a), Ph (1b)). Reactions of 1a with benzamide, acetamide, phenylacetamide, and trifluoroacetamide lead to the iridaoxazole derivatives Ir{κ2-C,O-[C(CH2tBu)NC(R)O]}{κ2-C,N-(MeC6H3-py)}2 (R = Ph (2), Me (3), CH2Ph (4), CF3 (5)) with a fac disposition of carbons and heteroatoms around the metal center. In 2-methyltetrahydrofuran and dichloromethane, water promotes the C-N rupture of the IrC-N bond of the iridaoxazole ring of 3-5 to form amidate-iridium(III)-hydroxycarbene derivatives Ir{κ1-N-[NHC(R)O]}{κ2-C,N-(MeC6H3-py)}2{═C(CH2tBu)OH} (R = Me (6), CH2Ph (7), CF3 (8)). In contrast to 1a, dimer 1b reacts with benzamide and acetamide to give Ir{κ4-N,C,C',O-[py-MeC6H3-C(CH2-C6H4)NHC(R)O]}{κ2-C,N-(MeC6H3-py)}(R = Ph (9), Me (10)), which bear a N,C(sp3),C(sp2),O-tetradentate ligand resulting from a triple coupling (an alkynyl ligand, an amide, and a coordinated aryl group) and a C-H bond activation at the metal coordination sphere. Complexes 2-4 and 6-10 are emissive upon photoexcitation, in orange (2-4), green (6-8), and yellow (9 and 10) regions, with quantum yields between low and moderate (0.01-0.50) and short lifetimes (0.2-9.0 μs). Show less
no PDF DOI: 10.1021/acs.inorgchem.2c03522
Ir imaging synthesis
Matt Rammo, Aleksander Trummal, Merle Uudsemaa +9 more · 2022 · Chemistry – A European Journal · Wiley · added 2026-04-20
AbstractLipophilic fluorophores are widely implemented in nonlinear microscopy; however, few existing membrane‐specific probes combine the high brightness of two‐photon excited fluorescence (2PEF) wit Show more
AbstractLipophilic fluorophores are widely implemented in nonlinear microscopy; however, few existing membrane‐specific probes combine the high brightness of two‐photon excited fluorescence (2PEF) with pH sensitivity. Herein we describe four novel two‐photon excited fluorophores, based on a coumarin 151 core structure, where lipophilicity is induced by a covalently attached phosphazene moiety. Changing the environmental acidity using trifluoromethanesulfonic (triflic) acid leads to profound changes in the linear fluorescence and 2PEF characteristics, due to chromophores’ switching between neutral‐ and protonated forms. We characterize this dependence by measuring the two‐photon absorption (2PA) spectra over the region λ2PA=550–1000 nm, observing 2PA cross sections of σ2PA=10–20 GM, with an associated 2PEF brightness of 10–13 GM, in neutral solutions of both acetonitrile and n‐octanol. Although quantum chemical modelling and NMR measurements show that, at high chromophore concentrations, protonation may be accompanied by a dimerization process, these dimers likely do not form at the lower concentrations used in optical spectroscopy. Show less
no PDF DOI: 10.1002/chem.202103707
NMR imaging
Jaehun Yi, Sanghun Yeou, Nam Ki Lee · 2022 · Journal of the American Chemical Society · ACS Publications · added 2026-04-20
Z-DNA, a noncanonical helical structure of double-stranded DNA (dsDNA), plays pivotal roles in various biological processes, including transcription regulation. Mechanical stresses on dsDNA, such as t Show more
Z-DNA, a noncanonical helical structure of double-stranded DNA (dsDNA), plays pivotal roles in various biological processes, including transcription regulation. Mechanical stresses on dsDNA, such as twisting and stretching, help to form Z-DNA. However, the effect of DNA bending, one of the most common dsDNA deformations, on Z-DNA formation is utterly unknown. Here, we show that DNA bending induces the formation of Z-DNA, that is, more Z-DNA is formed as the bending force becomes stronger. We regulated the bending force on dsDNA by using D-shaped DNA nanostructures. The B-Z transition was observed by single-molecule fluorescence resonance energy transfer. We found that as the bending force became stronger, Z-DNA was formed at lower Mg2+ concentrations. When dsDNA contained cytosine methylations, the B-Z transition occurred at 78 mM Mg2+ (midpoint) in the absence of the bending force. However, the B-Z transition occurred at a 28-fold lower Mg2+ concentration (2.8 mM) in the presence of the bending force. Monte Carlo simulation suggested that the B-Z transition stabilizes the bent form via the formation of the B-Z junction with base extrusion, which effectively releases the bending stress on DNA. Our results clearly show that the bending force facilitates the B-Z transition under physiological salt conditions. Show less
no PDF DOI: 10.1021/jacs.2c02466
imaging
Bernadette Mohr, Kirill Shmilovich, Isabel S. Kleinwächter +3 more · 2022 · Chemical Science · Royal Society of Chemistry · added 2026-04-20
Subtle variations in the lipid composition of mitochondrial membranes can have a profound impact on mitochondrial function. The inner mitochondrial membrane contains the phospholipid cardiolip Show more
Subtle variations in the lipid composition of mitochondrial membranes can have a profound impact on mitochondrial function. The inner mitochondrial membrane contains the phospholipid cardiolipin, which has been demonstrated to act as a biomarker for a number of diverse pathologies. Small molecule dyes capable of selectively partitioning into cardiolipin membranes enable visualization and quantification of the cardiolipin content. Here we present a data-driven approach that combines a deep learning-enabled active learning workflow with coarse-grained molecular dynamics simulations and alchemical free energy calculations to discover small organic compounds able to selectively permeate cardiolipin-containing membranes. By employing transferable coarse-grained models we efficiently navigate the all-atom design space corresponding to small organic molecules with molecular weight less than ≈500 Da. After direct simulation of only 0.42% of our coarse-grained search space we identify molecules with considerably increased levels of cardiolipin selectivity compared to a widely used cardiolipin probe 10-N-nonyl acridine orange. Our accumulated simulation data enables us to derive interpretable design rules linking coarse-grained structure to cardiolipin selectivity. The findings are corroborated by fluorescence anisotropy measurements of two compounds conforming to our defined design rules. Our findings highlight the potential of coarse-grained representations and multiscale modelling for materials discovery and design. Show less
📄 PDF DOI: 10.1039/D2SC00116K
ML imaging mitochondria
Elena Dallerba, David Hartnell, Mark J. Hackett +2 more · 2022 · Macromolecular Chemistry and Physics · Wiley · added 2026-04-20
AbstractWell‐defined copolymers containing luminescent iridium and hybrid iridium/rhenium fragments are prepared utilizing parent poly(n‐butyl acrylamide‐co‐N‐(1H‐tetrazol‐5‐yl) acrylamide) as macromo Show more
AbstractWell‐defined copolymers containing luminescent iridium and hybrid iridium/rhenium fragments are prepared utilizing parent poly(n‐butyl acrylamide‐co‐N‐(1H‐tetrazol‐5‐yl) acrylamide) as macromolecular chelating species. The parent (co)polymers are prepared via the modification of a precursor poly(pentafluorophenyl acrylate) (polyPFPA) homopolymer, prepared by reversible addition‐fragmentation chain transfer polymerization, with n‐butylamine and 5‐aminotetrazole. Reaction of the parent copolymers with [Ir2(ppy)4(μ−Cl2)] (ppy = 2‐phenylpyridine) yields modified copolymers containing the Ir(ppy)2 fragment as a pendent group. Attachment of the Ir species is confirmed by a combination of photophysical studies, UV–Vis spectroscopy, and visually under irradiation with UV light. Importantly, it is demonstrated that the chelation of the Ir(ppy)2 fragment to a polymeric scaffold does not impact the fundamental photophysical properties of the Ir species. Attachment of a second luminescent metal species, Re(CO)3(phen) (phen = 1,10‐phenanthroline), gives hybrid materials containing Re(I) and Ir(III). The photophysical properties of these hybrid materials are consistent with the presence of both metal species and indicate the occurrence of energy transfer phenomena from the polymer‐bound Ir to Re metal centers. Finally, it is demonstrated that the Ir modified polymers and the Ir/Re hybrid materials offer potential in tissue imaging applications with scope to tune both luminescent properties and biological specificity as evidenced from preliminary brain tissue staining experiments. Show less
no PDF DOI: 10.1002/macp.202200021
Co Ir Re imaging pyridine synthesis tetrazole
Puerta A, González-Bakker A, Santos G +1 more · 2022 · Molecules · MDPI · added 2026-04-20
Natural products represent an excellent source of unprecedented anticancer compounds. However, the identification of the mechanism of action remains a major challenge. Several techniques and methodolo Show more
Natural products represent an excellent source of unprecedented anticancer compounds. However, the identification of the mechanism of action remains a major challenge. Several techniques and methodologies have been considered, but with limited success. In this work, we explored the combination of live cell imaging and machine learning techniques as a promising tool to depict in a fast and affordable test the mode of action of natural compounds with antiproliferative activity. To develop the model, we selected the non-small cell lung cancer cell line SW1573, which was exposed to the known antimitotic drugs paclitaxel, colchicine and vinblastine. The novelty of our methodology focuses on two main features with the highest relevance, (a) meaningful phenotypic metrics, and (b) fast Fourier transform (FFT) of the time series of the phenotypic parameters into their corresponding amplitudes and phases. The resulting algorithm was able to cluster the microtubule disruptors, and meanwhile showed a negative correlation between paclitaxel and the other treatments. The FFT approach was able to group the samples as efficiently as checking by eye. This methodology could easily scale to group a large amount of data without visual supervision. Show less
📄 PDF DOI: 10.3390/molecules27165261
ML anticancer imaging
Nina Kasyanenko, Zhang Qiushi, Vladimir Bakulev +2 more · 2022 · Polymers · MDPI · added 2026-04-20
Platinum anticancer drugs inhibit the division of cancer cells through a DNA binding mechanism. The bimetallic platinum compounds have a possibility for blocking DNA replication via the cross-linking Show more
Platinum anticancer drugs inhibit the division of cancer cells through a DNA binding mechanism. The bimetallic platinum compounds have a possibility for blocking DNA replication via the cross-linking of DNA functional groups at different distances. Many compounds with metals of the platinum group have been tested for possible antitumor activity. The main target of their biological action is a DNA molecule. A combined approach to the study of the interaction of DNA with biologically active compounds of this type is proposed. The capabilities of various methods (hydrodynamic, spectral, microscopy) in obtaining information on the type of binding of coordination compounds to DNA are compared. The analysis of DNA binding with platinum binuclear compounds containing pyrazine, tetrazole, 5- methyltetrazole, 3-propanediamine as bridging ligands in a solution was carried out with the methods of circular dichroism (CD), luminescent spectroscopy (LS), low gradient viscometry (LGV), flow birefringence (FB) and atomic force microscopy (AFM). The competitive binding of different platinum compounds to DNA and the analysis of platinum attachment to DNA after protonation of its nitrogen bases simply indicates the involvement of N7 guanine in binding. Fluorescent dye DAPI was also used to recognize the location of platinum compounds in DNA grooves. DNA conformational changes recorded by variations in persistent length, polyelectrolyte swelling, DNA secondary structure, and its stability clarify the molecular mechanism of the biological activity of platinum compounds. Show less
no PDF DOI: 10.3390/polym14102044
DNA-binding Pt anticancer imaging tetrazole
M. Jin, H. Itamochi, J. Kigawa +532 more · 2021 · Pharmaceuticals · MDPI · added 2026-04-20
M. Jin, H. Itamochi, J. Kigawa, M.J. McKeage, K.H. Lee, M.S. Hyun, H.K. Kim, H.M. Jin, J. Yang, H.S. Song, Y.R. Do, H.M. Ryoo, J.S. Chung, D.Y. Zang, R.G. Kenny, S.W. Chuah, A. Crawford, C.J. Marmion, T.C. Johnstone, K. Suntharalingam, S.J. Lippard, S. Dilrub, G.V. Kalayd, X.Y. Wang, Z.J. Guo, A.A. Argyriou, P. Polychronopoulos, G. Iconomou, E. Chroni, H.P. Kalofonos, S.R. McWhinney, R.M. Goldberg, H.L. McLeod, Y.Z. Min, C.Q. Mao, S.M. Chen, G.L. Ma, J. Wang, Y.Z. Liu, D. Wang, V. Brabec, O. Hrabina, J. Kasparkova, S. Usanova, A. Piée-Staffa, U. Sied, J. Thomale, A. Schneider, B. Kaina, B. Köberle, W. Sakai, E.M. Swisher, B.Y. Karlan, M.K. Agarwal, J. Higgins, C. Friedman, E. Villegas, C. Jacquemont, D.J. Farrugia, F.J. Couch, G.Y. Park, W.J. Guo, Y.M. Zhang, L. Zhang, B. Huang, F.F. Tao, W. Chen, Q. Xu, Y. Sun, I.A. Riddell, J. Malina, N.P. Farrell, S.M. Alexander, W. Lin, K.S. Lovejoy, M. Serova, I. Bieche, S. Emami, M. D’Incalci, M. Broggini, E. Erba, C. Gespach, E. Cvitkovic, S. Faivre, W. Zhou, M. Almeqdadi, M.E. Xifaras, Ö.H. Yilmaz, J.J. Wilson, J.P. Macquet, J.L. Butour, M.J. Cleare, J.D. Hoeschele, W.I. Sundquist, D.P. Bancroft, L.S. Hollis, J.N. Burstyn, W.J. Heiger-Bernays, S.F. Bellon, K.J. Ahmed, A.R. Amundsen, E.W. Stern, S. Zhang, J.E. Shima, L.L. Lagpacan, Y. Shu, A. Lapuk, Y. Chen, T. Komori, J.W. Gray, X. Chen, R.C. Todd, M.S. McCormick, J.A. D’Aquino, J.T. Reardon, A. Sancar, K.M. Giacomini, G.Y. Zhu, X.H. Huang, Y. Song, A. Casini, J. Reedijk, M.W. Kellinger, J. Chong, A.A. Almaqwashi, M.N. Naufer, M.C. Williams, M.T. Gregory, Y.S. Lee, W. Yang, H. Baruah, C.L. Rector, S.M. Monnier, U. Bierbach, R. Guddneppanavar, G. Saluta, G.L. Kucera, J.R. Choudhury, A.R. Kheradi, B.D. Steen, C.S. Day, C.L. Smyre, T.E. Kute, G.V. Kalayda, B.A.J. Jansen, P. Wielaard, H.J. Tanke, C. Molenaar, M. Ferrari, J. Brouwer, S.D. Wu, C.C. Zhu, Y.J. Song, Y.Z. Li, C.L. Zhang, Z. Yu, W.J. He, Y.F. He, Z.F. Chen, S.P. Zhang, L. Shen, Z.Z. Zhu, J. Zhang, C. Zhang, R.L. Guan, X.X. Liao, C. Ouyang, T.W. Rees, J.P. Liu, L.N. Ji, H. Chao, S. Bonnet, L.M. Dabids, B. Kleemann, Z.J. Zhou, J.B. Song, L.M. Nie, X.Y. Chen, M. Ethirajan, Y.H. Chen, P. Joshi, R.K. Pandey, A. Naik, R. Rubbiani, G. Gasser, B. Spingler, G.C. Yu, S. Yu, M.L. Saha, J. Zhou, T.R. Cook, B.C. Yung, J. Chen, Z.W. Mao, F.W. Zhang, A.M. Santoro, M.C. Lo Giudice, A. D’Urso, R. Lauceri, R. Purrello, D. Milardi, I.O. Bacellar, T.M. Tsubone, C. Pavani, M.S. Baptista, T.T. Tasso, L.M. Mattiazzi, T.V. Acunha, B.A. Iglesias, G.K. Couto, B.S. Pacheco, V.M. Borba, J.C.R. Junior, T.L. Oliveira, N.V. Segatto, F.K. Seixas, T. Collares, X.J. Hu, K. Ogawa, S. Li, T. Kiwada, A. Odani, X.L. Xu, F.W. Lin, Y. Du, X. Zhang, J. Wu, Z.K. Xu, X. Li, B.D. Zheng, X.H. Peng, S.Z. Li, J.W. Ying, Y. Zhao, J.D. Huang, J. Yoon, R.C.H. Wonga, P.C. Lo, D.K.P. Ng, K. Mitra, M. Samsó, C.E. Lyonsb, M.C.T. Hartman, J.F. Mao, J.H. Zhu, M.K. Raza, S. Gautam, A. Garai, P. Kondaiah, A.R. Chakravarty, B. Wang, H.X. Yuan, Z. Liu, C.Y. Nie, L.B. Liu, F.T. Lv, Y.L. Wang, S. Wang, X.L. Xue, H.C. Chen, Y. Bai, X.C. Shi, Y. Jiao, Z.Y. Chen, Y.P. Miao, C. Settembre, A. Fraldi, D.L. Medina, A. Ballabio, S.R. Bonam, F.J. Wang, S. Muller, A.V. Klein, T.W. Hambley, C.G. Qian, H.B. Fang, H.K. Liu, H. Yuan, W.T. Liu, Y.F. Zhong, L.Y. Liu, C.T. Shen, W.J. Zeng, F.Y. Wang, D.Z. Yang, X.H. Zheng, G. Mu, T.P. Zhang, Q. Cao, H. Zhang, Y.W. Zhou, Y. Shen, P.Z. Qin, Y. Li, E. Freisinger, R.K.O. Sigel, B. Dumat, G. Bordeau, E. Faurel-Paul, F. Mahuteau-Betzer, N. Saettel, G. Metge, C. Fiorini-Debuisschert, F. Charra, M.P. Teulade-Fichou, C.P. Tan, U. Basu, B. Banik, R. Wen, R.K. Pathak, S. Dhar, M. Kansara, M.T. Teng, M.J. Smyth, D.M. Thomas, E. Alpaslan, H. Yazici, N.H. Golshan, K.S. Ziemer, T.J. Webster, D.E. Reed, K.M. Shokat, J.S. Whelan, L.E. Davis, G. Makris, E.D. Tseligka, I. Pirmettis, M.S. Papadopoulos, I.S. Vizirianakis, D. Papagiannopoulou, Z.Q. Zhang, C. Luo, K. Wang, S.R. Zhang, H. Hamidi, J. Ivaska, T. Chatzisideri, S. Thysiadis, S. Katsamakas, P. Dalezis, I. Sigala, T. Lazarides, E. Nikolakaki, D. Trafalis, O.A. Gederaas, M. Lindgren, A. Zamora, A. Gandioso, A. Massaguer, S. Buenestado, C. Calvis, J.L. Hernández, F. Mitjans, V. Rodríguez, J. Ruiz, V. Marchán, T. Wu, Y. Dai, A.A. Franich, M.D. Živković, T. Ilić-Tomić, I.S. Đorđević, J. Nikodinović-Runić, A. Pavić, G.V. Janjić, S. Rajković, U.E. Martinez-Outschoorn, M. Peiris-Pages, R.G. Pestell, F. Sotgia, M.P. Lisanti, Y.H. Yang, S. Karakhanova, W. Hartwig, J.G. D’haese, P.P. Philippov, J. Werner, A.V. Bazhin, M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, D.C. Wallace, S. Marrachea, R.W. Taylor, D.M. Turnbull, P. Bouwman, J. Jonkers, C. Holohan, S. Van Schaeybroeck, D.B. Longley, P.G. Johnston, S. Fulda, L. Galluzzi, G. Kroemer, N. Lomeli, K.J. Di, J. Czerniawski, J.F. Guzowski, D.A. Bota, Y. Guo, D.F. Song, Z.H. Wang, Y.J. Wang, H.M. Zhang, Z.J. Gan, N. Muhammad, P. Imming, C. Sinning, A. Meyer, R. Ramsay, K. Tipton, N.K. Tonks, L.P. Lu, M.L. Zhu, C.X. Yuan, W.R. Wang, J.W. Wang, X.H. Li, Y.B. Wu, S.D. Li, S. Xing, X.Q. Fu, D.W. Zhang, Y.M. Yip, L.B. Li, S.N. Li, J.J. Li, W.Q. Dai, Q.H. Zhang, J. Feng, L.W. Wu, T. Liu, Q. Yu, S.Z. Xu, W.W. Wang, K. Muhammad, N. Sadia, Z.Y. Pan, P.A. Waghorn, M.R. Jackson, V. Gouverneur, K.A. Vallis, A. Paul, B. Maji, S.K. Misra, A.K. Jain, K. Muniyappa, S. Bhattacharya, G.B. Huang, S. Chen, Q.P. Qin, J.R. Luo, M.X. Tan, Z.F. Wang, B.Q. Zou, H. Liang, X.L. Huang, Y. Zhang, S.L. Wang, H.H. Zou, L. Wang, Z.X. Long, Z.K. Song, T. Xie, S.H. Zhang, Y.C. Liu, B. Lin, M. Sabbatini, I. Zanellato, M. Ravera, E. Gabano, E. Perin, B. Rangone, D. Osella, D.Y.Q. Wong, W.W.F. Ong, W.H. Ang, K.B. Huang, H.W. Feng, H.J. Luo, Y. Long, T.T. Zou, A.S.C. Chan, R. Liu, K. Al-Khayal, M.A. Vaali-Mohammed, M. Elwatidy, T. Bin Traiki, O. Al-Obeed, M. Azam, Z. Khan, M. Abdulla, R. Ahmad, K. Choroba, B. Machura, L.R. Raposo, J.G. Małecki, S. Kula, M. Pająk, K. Erfurt, A.M. Maroń, A.R. Fernandes, X.M. Tang, X. Wang, Y.N. Liu, G. Ferraro, T. Marzo, T. Infrasca, A. Cilibrizzi, R. Vilar, L. Messori, A. Merlino, Z. Li, Y. Gan, Y.H. Yin, W.C. Zhang, J.F. Yang, Y.X. Tang, Y.B. Dai, C. Icsel, V.T. Yilmaz, B. Cevatemre, M. Aygun, E. Ulukaya, I. Khan, B. Maity, J.Y. Zhang, C. Tu, J. Lin, J. Ding, L.P. Lin, Z.M. Wang, C. He, C.H. Yan, X.Z. You Show less
Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side Show more
Platinum-based anticancer drugs represented by cisplatin play important roles in the treatment of various solid tumors. However, their applications are largely compromised by drug resistance and side effects. Much effort has been made to circumvent the drug resistance and general toxicity of these drugs. Among multifarious designs, monofunctional platinum(II) complexes with a general formula of [Pt(3A)Cl] + (A: Ammonia or amine) stand out as a class of “non-traditional” anticancer agents hopeful to overcome the defects of current platinum drugs. This review aims to summarize the development of monofunctional platinum(II) complexes in recent years. They are classified into four categories: fluorescent complexes, photoactive complexes, targeted complexes, and miscellaneous complexes. The intention behind the designs is either to visualize the cellular distribution, or to reduce the side effects, or to improve the tumor selectivity, or inhibit the cancer cells through non-DNA targets. The information provided by this review may inspire researchers to conceive more innovative complexes with potent efficacy to shake off the drawbacks of platinum anticancer drugs. Show less
📄 PDF DOI: 10.3390/ph14020133
Pt anticancer imaging photoactivated review